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ABSTRACT

In this study, a simple method of performing treatment dose verification for Intensity
Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy
(VMAT) using an Electronic Portal Imaging Device (EPID) was investigated. This
work was based on a model for IMRT verification using Varian EPIDs presented by
Lee et al. (2009). The method presented by Lee et al. (2009) was modified and
extended upon to include equipment from different vendors, different treatment
planning systems, and to include verification of VMAT.
The EPID dose verification QA system was designed and tested using an Elekta
AxesseTM LINAC with an iViewGTTM EPID (Elekta AB, Sweden), and a Siemens
Oncor ImpressionTM LINAC with an OptiVue 1000STTM EPID panel (Siemens
Medical Solutions USA, Inc, USA).

The EPID dose verification system compared flood field (FF) corrected EPID images
(calibrated to absolute dose) and dose fluences generated by a treatment planning
system (TPS) at a pre-determined depth in water (dref). The depth in water was
determined as the depth in water that had closest agreement to the dose response
properties of the EPID. Methods to determine dref are described and validation of the
dosimetry system have been made with Step and Shoot IMRT and dynamic VMAT
fields for 6 and 10 MV beam energies. Two different planning systems were used for
patient field generation for comparison with the measured EPID fluences, XiO®
v4.64 and Monaco® v3.10 (Elekta AB, Stockholm, Sweden).

All measured IMRT and VMAT patient fields achieved greater than 95% agreement
with the planning fluences (using 3 cGy / 3 mm gamma criteria) and were
comparable to the pass-rates obtained by using the MapCHECK® two-dimensional
diode array (Sun Nuclear Corporation, Florida, USA) as per current department
procedure for IMRT dose verification. The dosimetry system developed using the
EPID was found to be a suitable tool for use in clinical pre-treatment dose
verification and has since been implemented clinically.
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1 INTRODUCTION

1.1

PROJECT AIMS

Accurate and efficient pre-treatment dose verification of Intensity Modulated
Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) is
required in radiotherapy cancer treatment (ICRU Report 83 2010). An increase in
utilisation of complex treatment techniques such as IMRT and VMAT which require
individual patient pre-treatment dose verification has increased the workload of
radiotherapy departments due to equipment, time and financial considerations
associated with IMRT and VMAT treatment and per-patient quality assurance (QA).
Finite resources available in most departments necessitate that an IMRT / VMAT
dosimetry system must be cost-effective, efficient, and accurate to ensure the
implementation of an IMRT / VMAT program is practical. In a department where
multiple machines are capable of IMRT / VMAT deliveries, pre-treatment dose
verification QA scheduled at the same time on multiple machines produces strain on
equipment and staff resources.

Electronic Portal Imaging Devices (EPIDs) are a standard accessory with all modern
Linear Accelerators (LINACs) for patient positioning and verification prior to
radiotherapy treatment (Image-Guided Radiation Therapy (IGRT)) (Kirby and
Glendinning 2006). The use of EPIDs for dose verification has been demonstrated
using a variety of techniques with a comprehensive review presented by Van Elmpt
et al. (2008). Most of the reported methods for EPID dosimetry require specialised
skills that are not widely available, limiting the widespread implementation of EPID
dosimetry. This project focused on a simple method for the quantification of absolute
dose obtained from images acquired with EPIDs, and the subsequent development
and implementation of a vendor-independent model for patient-specific dose
verification of IMRT and VMAT treatment plans.

The specific aims of this project were to:
i.

Determine the dosimetric properties of EPIDs in megavoltage radiation
therapy fields. This included evaluation of panel reproducibility, linearity
1

with dose, and field size dependence of flood field (FF) corrected images
from a Siemens OptiVue 1000STTM and Elekta iViewGTTM EPID.
ii.

Determine a reference depth in water, dref where the dose response of each
EPID detector panel closely corresponds to the dose response of reference
dosimeters in water.

iii.

Calibrate EPID pixel values to dose at the corresponding dref, then compare
dose profiles measured using calibrated EPIDs for open fields, and highlymodulated test patterns, to the dose profiles generated by a treatment
planning system (TPS) at dref for these fields.

iv.

Develop and evaluate this technique as a method for patient-specific dose
verification QA of IMRT and VMAT plans using any combination of EPID,
TPS, beam energy and delivery technique. Demonstrate the feasibility of this
method for routine clinical IMRT and VMAT QA.

1.2

CANCER

Cancer describes a disease in which some normal cells of the body become
genetically mutated and, without undergoing cellular death, can continue to multiply
out of control in this mutated state thus causing the formation of a tumour. These
mutated cells can be confined to a single site in the body within a single tumour
(primary tumour) or travel to other sites in the body and continue to proliferate
(metastases) (AIHW 2010).

The latest report from the Australian Institute of Health and Welfare (AIHW) on the
incidence of cancer in Australia was published in 2010 and estimated that in 2010
there would be a total of 539 800 people with various forms of the disease, which
was based on the 2007 diagnosis rate of 108 368 new cases. Cancer accounted for a
total of 19% of the total burden of disease for the population at the time of the
publication (AIHW 2010).

1.3

CANCER TREATMENT

Three principle techniques are used for the management of malignant disease;
surgery, chemotherapy and radiation therapy. The treatment technique and prognosis
2

following treatment is dependent on the tumour type, site and staging. Often a patient
will undergo a treatment regime using a combination of techniques to improve
tumour control and outcome (Wang 2000).

1.3.1 Surgery
The goal of radical surgery for tumour removal is to extract the gross palpable
tumour and any microscopic extensions of the disease. The microscopic extensions
are difficult to detect and to extract surgically. As a result the gross tumour volume is
sometimes removed by surgery with the suspected microscopic extensions targeted
with radiotherapy (Wang 2000).

1.3.2 Chemotherapy
Chemotherapy is the application of chemically toxic drugs into the body that target
tumour cells to achieve cell kill. The chemotherapeutic drugs act on fast-proliferating
(rapidly dividing) cells to impair mitotic function. Chemotherapy is administered on
a regimented cycle to optimise the kill of the targeted cells whilst minimising kill to
the non-targeted cells (Airley 2009). Chemotherapy is a systemic treatment that is
often combined with localised therapies such as surgery and/or radiotherapy in the
treatment of cancer, where surgery or radiotherapy targets the local disease and
chemotherapy targets microscopic spread of the disease.

1.3.3 External Beam Radiation Therapy
Radiation therapy involves the use of ionising radiation to cause irreversible damage
to the tumour cells inducing cell death. The goal of radiotherapy is to target the
tumour volume whilst sparing the surrounding normal healthy tissue by optimising
beam shapes and angles (Webb 2003).

External beam radiation therapy (EBRT) uses a radiation beam incident externally on
the patient to treat an internal tumour volume. This is achieved through the use of a
linear accelerator (LINAC), or less commonly a Cobolt-60 or Proton Accelerator.
3

For the purpose of this Masters thesis EBRT will be discussed in terms of LINAC
generated x-ray beams.

EBRT consists of three phases: image acquisition, planning and treatment. Image
acquisition is performed using modern imaging equipment such as Computed
Tomography (CT) scanners, Magnetic Resonance Imagers (MRI) and, more recently,
Positron Emission Tomography (PET) imagers. These imaging modalities allow the
reconstruction of patient data into a 3-D data set for planning purposes. For accurate
localisation of disease and radiotherapy treatment planning, registration of different
imaging modalities is required where CT images are the reference data set since it
provides accurate spatial and radiological information of the patient. Image
registration is the correlation of two or more data sets to identify and match
corresponding structures (Khan 2010). Registration techniques using CT data with
MRI (which provides higher soft tissue contrast) allows more accurate tumour
delineation in regions such as the brain, and CT with PET (providing functional
information) allows accurate delineation of the active tumour volume extent. The
patient is scanned in the treatment position for reproducibility and accuracy of
planning (Meyer 2007). In radiotherapy, image registration can be rigid (where one
image data set is overlaid on another and shifted to provide the best match of
anatomy) or deformable where one image data set is manipulated / deformed to
match that of the reference data set. The most common deformable registration
method is that of the Demon’s method which is detailed by Wang et al. (2005).

The patient imaging data set is transferred to the Radiotherapy Treatment Planning
System (TPS). The TPS contains beam models of the individual LINACs in the
department. The model based data used for treatment planning is matched to
experimentally collected beam data during LINAC commissioning measurements.
The model based methods are able to calculate planned dose during a virtual
treatment to the patient image set using the beam data. The radiation oncologist
defines the target volume and prescribes the treatment, including dose levels to the
target and dose limits to critical structures. The radiation therapist develops a
treatment plan in the TPS. Once the treatment plan has been optimised and approved
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for treatment, it is exported to the Record and Verify (R&V) system and eventually
to the LINAC for treatment (Khan 2010).

Treatment is performed in the position used for image acquisition. The patient is set
up on the treatment couch and aligned with the external lasers to the planned
isocentre (from the TPS coordinates). Prior to treatment the patient’s position can be
verified using a variety of available imaging technologies (Jaffray et al. 2007). For
example megavoltage (MV) EPIDs or kilovoltage (kV) cone beam CT (kV CBCT)
may be acquired and registered to reference images to align the patient to the planned
position. Alignment is performed using matches between anatomy (bony anatomy or
fiducial markers) or using the field edges between the portal images acquired at the
time of treatment and the planning digital reconstructed radiographs (DRRs)
produced by the TPS. Once the position is verified, the patient is treated in small
fractions over several weeks to achieve the total dose required for tumour kill. Small
fractions (~2 Gy) with daily breaks are used due to the specific radiobiology of the
tumour cells (Wigg 2001).

1.4

RADIATION THERAPY TREATMENT METHODS

1.4.1 3D Conformal Radiation Therapy
3D conformal radiation therapy (3DCRT) was implemented in radiotherapy
following the introduction of the CT scanner in 1972 (Webb 2001(b)). The CT
scanner can be used to acquire a 3D tomographic volume of the patient anatomy in
the specified area to be imaged.

The reconstructed CT scan was imported into the TPS where the target (tumour) and
any organs at risk were able to be delineated by the radiation oncologist on each of
the acquired 2D CT slices, forming a reconstructed 3D patient volume. Beam
arrangements and shapes were then optimised as a result of the virtual simulation on
the 3D volume, allowing a more conformal treatment and target coverage than
previously available.
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3DCRT can be used for all treatment sites in radiotherapy, however with improved
3D imaging and contouring, the complexity of target volumes and organs at risk
surrounding the volumes demanded a more conformal technique.

Figure 1.4.1: Comparison of radiotherapy treatment delivery techniques from 2-D,
to 3D-CRT to Intensity Modulated Radiation Therapy (clockwise from top left)
(Webb 2003).

1.4.2 Intensity Modulated Radiation Therapy
IMRT is a highly conformal radiation therapy technique using Multi-Leaf
Collimators (MLCs) to modulate the dose of radiation within each treatment field,
optimising the composite dose distribution in the tumour volume, while limiting the
dose to surrounding normal tissues (Kahn 2010). This technique uses multiple gantry
angles, and beam shapes with inversely calculated spatially varying energy fluence,
optimised to achieve a desired dose distribution. A characteristic of IMRT is the
ability to produce conformal distributions to targets which contain concave (i.e. reentrant) surfaces, these dose distributions are characterised by steep dose gradients at
the tumour edges (Palta et al. 2003).

IMRT may be delivered using compensators or MLCs. Compensators are metal
blocks placed in the accessory mount of the LINAC treatment head that act to
modulate the fluence of the radiation beam to the desired shape across the treatment
field. The compensator modulates the beam to produce maximum dose to the target
and minimal to the surrounding tissues. Each patient would have a set of individual
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compensators prepared for their treatment from information obtained from the TPS
(Chang et al. 2004). This method of IMRT delivery is not used commonly, with
treatment staff having to enter the room to change compensators for each beam, and
the cost of the attenuating material being too high to sustain this technique for large
numbers of patients.

Figure 1.4.2.1: Compensator used for IMRT delivery. The different thickness of
material modulates the beam to increase tumour kill and decrease dose to proximal
organs at risk (Javedan et al. 2008).

Small MLC shaped apertures/segments are commonly used for IMRT delivery using
modern LINACs. MLCs are collimation systems consisting of a high density,
attenuating material (predominantly an alloy of tungsten) that can be ancillary to or
may replace one or both jaws in the LINAC treatment head. The MLC system
consists of opposed leaf pairs that can shape the field in a way similar to a jaw or in a
way that is highly conformal to the tumour/target shape (Huq et al. 2002). Unlike
compensators, MLCs can be driven into place automatically via computer control.

Figure 1.4.2.2: MLC leaves shaped to conform to a tumour volume (Height et al.
2012).
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The delivered beam at each gantry angle is subdivided into segments with uniform
beam intensities. The segments are delivered in sequence one at a time in a way that
the segments can build on top of one another to form spatially varying intensities
across the field. Segments can also be delivered with different MU per segment so
this also varies the dose delivered in each segment. The process is achieved by
computer control of MLC segments and beam generating systems (Kahn 2010). Two
delivery options are available for MLC delivered IMRT: dynamic MLC IMRT and
segmental MLC IMRT.

1.4.2.1 Dynamic MLC IMRT
Dynamic MLC IMRT (dMLC) is a technique whereby the dose is delivered with the
MLCs moving across the radiation field to shape the beam. dMLC is used for some
IMRT deliveries and for all rotational IMRT treatments. When the delivery involves
dynamic movement of the leaves from one side to another, this is called dynamic
sliding window delivery of IMRT.

1.4.2.2 Static MLC IMRT
Static MLC IMRT (sMLC) uses static beams with different MLC shapes to form a
modulated beam. This technique of delivery is also known as Step-and-Shoot IMRT
as the segment shape is formed with the MLC leaves, the field is delivered (shoot),
and the beam is turned off while the next segment is being set by the MLCs (step).
Both Siemens and Elekta LINACs use the sMLC technique to deliver IMRT
treatments. Varian LINACs can deliver dMLC or sMLC treatments. The mode of
IMRT delivery usually depends on the planning system used to generate the patient
plan.

1.4.3 Volumetric Modulated Arc therapy
VMAT is an arc-based delivery approach that uses dMLC IMRT, variable dose-rate,
leaf speed and gantry speed to achieve dose conformality to the tumour and minimise
dose to surrounding tissues (Bedford et al. 2009). The method is derived from a
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technique developed by Yu (1995) called Intensity Modulated Arc Therapy (IMAT),
and by Otto (2007) called Volumetric Modulated Arc Therapy, which incorporated
gantry speed and dose rate variability. VMAT was developed to maximise the
number of treatment angles used (360°) for irradiation of the tumour volume in the
shortest amount of time (approximately 30% less time than for sIMRT) (AlvarezMoret et al. 2010). Typical treatment times are shorter for a VMAT plan compared to
IMRT as the treatment is a predominantly open aperture technique which hence
requires a smaller amount of MU delivered to achieve dose coverage. Time is also
gained due to the dynamic nature of the MLCs, and continuous delivery of dose with
gantry rotation. VMAT treatments involving complex targets may require delivery of
multiple arcs to achieve coverage of the PTV. This delivery increases total treatment
time and may not provide advantages over IMRT for total treatment time.

1.5

PATIENT IMAGING / TREATMENT VERIFICATION

The positioning of a patient on the treatment bed and visualisation of internal organs
and target volumes prior to treatment are crucial factors in the radiotherapy setting.
Positioning of the target volume can vary day-to-day (inter-fraction motion) and also
within the treatment time (intra-fraction motion). The ability to visualise (through
imaging) the position of the targeted area and correct for differences between the
time of planning and treatment is a crucial factor in the overall effectiveness of a
course of radiotherapy. Any positional differences in a patient’s anatomy between
planning and treatment can lead to a geometric miss of the tumour volume which
decreases the Tumour Control Probability (TCP) and increases dose to surrounding
normal tissues, this may lead to an increase in Normal Tissue Complication
Probability (NTCP) of the organ at risk (OAR) (Mundt et al. 2011).

Patient positioning was traditionally performed using radiographic film. This film
was placed beneath the patient, marked for position and irradiated. The film then had
to be processed and analysed for patient positioning purposes before the treatment
could begin. This process took 5 - 15 minutes to perform for each patient portal film
(Langmack 2001).
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With the development of digital imaging technology, on-board imaging panels have
become available for electronic patient imaging and are now standard on most
LINACs. EPIDs are large area detectors that can be used to generate radiographic
images with a relatively low dose of irradiation from the LINAC. The EPID image
obtained is directly transferred to patient positioning software for comparison with
the planned patient position. Shifts in patient position can then be applied following
online analysis using bony anatomy or field edge matching (Khan 2010). EPIDs
have also been used for matching to fiducial markers implanted in the prostate or
surrounding tissue for treatment of prostate cancer (Schiffner et al. 2007).

Figure 1.5.1: Linear accelerator fitted with an EPID (bottom) below the treatment
head and a KV source and a kV panel (right and left) perpendicular to the treatment
head/radiation beam (Ravindran et al. 2007).

EPIDs use the MV beam from the LINAC treatment head to create an image of the
patient. These images can offer good bony anatomy contrast and matching, but suffer
poor soft tissue contrast due to beam energy and penetration properties (Ravindran et
al. 2007).

To increase the contrast available for soft tissue and treatment sites such as the
prostate, kV imagers have been implemented on modern LINACs. The kV imaging
system consists of an x-ray tube and imaging panel placed orthogonal to the MV
beam direction. kV images have high soft tissue contrast, increased signal-to-noise
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(SNR) per unit dose and low-dose volumetric imaging capabilities when compared to
MV imaging techniques (Groh et al. 2002). KV imaging also delivers lower dose to
the patient than MV imaging; with ~0.1 cGy for a kV CBCT compared to ~1-8 cGy
respectively for orthogonal MV imaging for a head and neck treatment (Ding et al.
2011). Imaging dose from MV CBCT has also been investigated by Quinn et al.
(2011) for breast radiotherapy with doses < 4cGy measured for an 8 monitor unit
(MU) MV CBCT image. As a result patient kV imaging can be a preferred
alternative to MV imaging when deciding on imaging protocols due to the reduced
risk of secondary induced cancer to radiotherapy patients (Walters 2002).

Two-dimensional kV images can be acquired using the kV tube and detector
assembly in the direction orthogonal to the LINAC treatment head and hence the
radiotherapy beam, however when proximal organs at risk are involved the kV
projection images can be taken by rotating the LINAC gantry containing the kV
imager in an arc while acquiring kV projections. These projections are then
reconstructed as a three-dimensional CBCT image for more accurate target
localisation.

kV CBCT images have become popular for prostate imaging protocols due to the
volumetric soft tissue information and the ability to accurately match fiducial
markers in three-dimensions. Although better contrast is offered, a single CBCT
image can take up to a minute to acquire and the increased contrast may not be
required for all types of treatments. It must be noted, though, that the doses to
peripheral organs can be of concern using kV CBCT due to large volumes of normal
tissue being irradiated (Ravindran et al. 2007). The reproducibility of CT numbers
from kV CBCT render them more useful as image guidance images and they are not
widely used for adaptive re-planning. kV CBCT are more often used as a trigger for
adaptive re-planning that requires a rescan on a simulator CT device.

1.6

PATIENT DOSE VERIFICATION

The dose received by a patient to the target volume (tumour) and surrounding organ
at risks (OARs) is required by the ICRU to be within 95 – 107% of the prescription
dose (ICRU Report 50, 1993). All patient plans treated using EBRT require patient11

specific pre-treatment verification of delivered dose using an independent MU
checking program (3DCRT), and additional machine QA measurements of the
patient plan (IMRT / VMAT).

Patient-specific machine dose verification QA measurements are routinely performed
with single ion chambers for point dose measurements, and with film, ion chamber
and diode arrays for 2D dose fluence comparisons. These measurement techniques
involve the procurement of extra equipment for a department. The implementation of
kV imaging for image guidance and subsequent patient positioning has seen a
reduction in the use of the EPID for this purpose. Coincidentally there has been an
increase in the number of centres using the EPID for pre-treatment dosimetry
measurements during the reduction of the use of the device for patient image
guidance, with various techniques and algorithms developed by groups to implement
the EPID into routine patient-specific dose verification QA.

The use of EPID imaging panels to perform simple, vendor-independent pretreatment dose verification of patient-specific IMRT and VMAT plans is explored in
this Masters thesis. An in-depth literature review on IMRT and VMAT pre-treatment
dose verification QA is presented in Chapter 2, in particular the use of the EPID
panel for pre-treatment IMRT dose verification.
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2 LITERATURE REVIEW

In this chapter a detailed analysis about the properties of various EPIDs are
presented. In particular, several dosimetric properties of the devices are provided
when the imagers are used for dose verification of radiotherapy treatment fields.

2.1

PORTAL IMAGING

Portal images are used in the radiotherapy field as one of the imaging tools in the
IGRT and Adaptive Radiation Therapy (ART) process. An image of the patient is
acquired in the treatment position immediately prior to a treatment fraction and
compared to a reference image, typically a DRR. These DRRs are produced by the
treatment planning system from the patient CT dataset for selected treatment beams.
Portal images acquired at the time of treatment are compared to the DRRs by patient
geometry (bone) and by MLC/jaw edge matching (i.e. treatment portal shape). Shifts
of the patient support couch are performed based on this matching of the portal
image and DRR to achieve the closest correlation of patient treatment position to the
planning data (Webb 2001(a), Meyer 2007, Khan 2010, and Chen et al. 2011).

Figure 2.1.1: DRR (left) and EPI (right) comparison for a clinical head and neck
plan. Cross hairs on DRR and EPI denote the corresponding isocentres (Chen et al.
2011).

Portal images taken at MV energies have a reduced image quality when compared to
diagnostic radiographs taken at kV energies. The reduced image quality is due to the
nature of interactions of the higher energy x-rays in the patient or phantom and in the
detector panel. The predominant process of x-ray interaction at MV energies is
Compton scattering. The contrast in the MV image results from changes in density
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rather than atomic number, therefore at tissue-air interfaces the image quality is high,
but for imaging higher density materials such as bones, is significantly decreased
(Greene et al. 1997).

Advantages of EPID imaging relative to conventional film for positional verification
have been of significance and have led to the almost complete eradication of film in a
radiotherapy setting. Advantages include faster imaging and image verification,
computer-assisted anatomical structure matching and overlaying of acquired (EPID)
and predicted (DRR) images, digital image processing, transfer and storage. Image
processing available with EPID imaging includes the ability to adjust image contrast
and add different filters to the image to optimise image quality for position
verification (Kruse et al. 2002). Integration of computerised portal imaging systems
with radiotherapy record and verify systems also provides significant workflow
advantages as image acquisition and review can be performed at a single
workstation.

2.2

ELECTRONIC PORTAL IMAGING DEVICES

At present active matrix, flat panel imagers (AMFPIs) are the most utilised type of
EPID in radiotherapy centres. These devices consist of a large area pixelated array
overlaid by a thin x-ray converter (metal plate and scintillator) and an electronic
detection, acquisition, and analysis system (Antonuk 2002). The metal plate provides
build-up for the scintillator, generating electrons and x-rays generated through the
Compton Effect for interaction with the phosphor. The scintillator, upon interaction
with ionising radiation, emits visible light with one interaction producing thousands
of visible light photons (Attix 1986). The scintillator is directly coupled to a
photosensitive layer in the AMFPI EPID for both the Siemens OptiVue 1000STTM
and the Elekta iViewGTTM; this layer consists of 133 mg cm-2 terbium-activated
gadolinium oxysulphide, Gd2O2S:Tb (Juste 2010, Deshpande et al. 2011).
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Figure 2.2.1: Cross-section of the Elekta iViewGTTM a-Si EPIs (Elekta iViewGTTM
R3.02 – R3.4 corrective maintenance manual).

Light incident on the photosensor causes the production of an electron-hole pair.
The photosensor acts as a capacitive element, storing the integrated charge created by
the electron-hole production until readout (Antonuk 2002). Commercially available
AMFPI EPIDs consist of photosensors fabricated from hydrogenated amorphous
silicon (a-Si:H).

The AMFPI EPID pixelated array consists of thin film transistor (TFT) electronic
circuits. These circuits contain a thin film switch connecting a capacitor
(photosensor), consisting of a-Si:H, to the control and data circuitry. Application of
voltage to a switch determines its conductivity. A conductive switch allows the
integrated charge (from irradiation) to be transferred along the data circuitry to be
read out; a switch that is not conductive allows the integration of charge in the
capacitor when the panel is exposed to radiation. Switching of the voltage from one
row of switches to the next in the pixelated array allows the signal to be transferred
in the data circuitry to form an integrated image. Each complete read-out of the panel
is known as a ‘frame’.
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Figure 2.2.2: Schematic diagram of a corner of an AMFPI EPID. Note the control
and data circuitry surrounding each pixel element (Antonuk 2002).

EPID images are usually displayed as the average of several frames, the so-called
frame-average image. The total cumulative pixel values from an exposure can be
obtained by integrating the frames or by multiplying the frame-average image by the
number of frames acquired. (Chang et al. 2003).

Electronic circuitry is often situated around the perimeter of the active matrix of the
AMFPI. This provides a limit of the field sizes able to be imaged using the EPID at
extended SSDs due to radiation damage effects on the external circuitry. Typical
field sizes for the AMFPI at the level of the panel are approximately 41 x 41 cm2 for
the Siemens Optivue 1000STTM (Siemens Medical Solutions, Concord, California)
and the Elekta iViewGTTM (Elekta, Crawley, United Kingdom) and 40 x 30 cm2 for
the Varian aS1000 (Varian Medical Systems, Palo Alto, California).

The contribution of backscatter radiation from the detector arm has been examined
by Greer et al. 2007 for Varian machines. Robotic arm backscatter is negligible for
Siemens and Elekta units due to a lower density arm material, and the more uniform
material directly behind the detector compared to the Varian steel arm. As a result,
this thesis does not examine the effect of robotic arm backscatter due to the use of
Elekta and Siemens panels only.
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2.2.1 EPID Calibration
EPIDs require a calibration to correct the panel for LINAC beam characteristics and
inherent detector characteristics to produce the highest quality image for patient
positioning. The calibration process involves the acquisition of a dark field (DF)
image and a flood field (FF) image that are used in a calibration equation and
subsequently applied to all images acquired with the portal imager.

The DF signal is obtained by acquiring an image over the entire area of the EPID in
the absence of a radiation beam. The pixels in this DF image correspond to electronic
noise inherent in the detector system. The DF is influenced by the ambient
temperature (McDermott et al. 2003) and the long term stability has been seen to
vary over time due to radiation induced damage to the array (Louwe et al. 2004).

The FF is obtained by acquiring an image with the EPID in the presence of a uniform
radiation field over the entire detection area of the panel. This image is used to
correct for pixel sensitivities, and create a uniform response over the entire panel
area to a radiation beam. The flood field effectively removes variations in the beam
intensity across the panel area caused by the dose profile horns. This FF calibration
acts to optimise patient imaging contrast by eliminating the variations in the dose
profile. The FF calibration is acquired at regular intervals following manufacturer
recommendations to maintain image quality. The calibration process ensures any
pixels that may have undergone radiation induced changes or mechanical and
electrical damage are identified with and their response scaled appropriately to
produce a uniform image across the detector.

The calibration image can be obtained by dividing the pixels in the raw image (Iraw)
(x, y) by those in the FF image (IFF) (x, y), and subtracting the DF image from both
measurements (IDF) (x, y). The DF image can be used from the time of calibration, or
directly prior to measurements (Kairn et al. 2008).

 I ( x, y)  I DF ( x, y) 
I FF ( x, y )  I DF ( x, y)mean
I ( x, y )   raw
 I FF ( x, y)  I DF ( x, y ) 

(2.2.1)
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Calibration images are recommended to be taken with each nominal beam energy for
a LINAC using the largest field size possible. This is due to the variation in beam
intensity across the field and differences in beam profiles between energies (Herman
et al. 2001).

2.3

DOSIMETRIC CHARACTERISTICS OF EPIDS

A significant amount of research has been performed examining the dosimetric
characteristics of EPIDs. Antonuk (2002) and van Elmpt et al. (2008) have provided
in-depth literature reviews on the development, use and characterisation of EPIDs for
clinical dosimetry since clinical implementation.

2.3.1 Pixel Sensitivity
Individual pixels in EPID panels have responses that vary from the central axis pixel.
Pixel sensitivity is defined as the EPID pixel response to a uniform beam across the
detector and has been examined in detail by Greer (2005). The pixel sensitivity is a
parameter that is independent of the gain calibration (which corrects for off-axis
response of the panel), and can be applied to the whole panel for calibration and
imaging purposes. The pixel sensitivity is described by Greer (2005) as a change in
sensitivity of the individual pixels in an EPID panel, and the off-axis response as an
energy-dependent parameter relating to the phosphor layer. By irradiating an EPID in
different positions across the panel by a 10 x 10 cm2 field, a variation in EPID pixel
sensitivity could be mapped across the detector that was independent of the floodfield image.
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Figure 2.3.1.1: EPID pixel sensitivity map across the central axis of a Varian EPID
(Greer 2005).

This pixel sensitivity was used to generate a polynomial that was applied to all
subsequent raw EPID images to improve off-axis pixel response for dosimetry
purposes. This method was implemented by Greer (2005) to raw-EPID images. Other
methods to model the off-axis response of the EPID are presented by Parent et al.
(2007) using Monte Carlo simulation.

2.3.2 Linearity
The dose linearity of EPIDs has been studied by Budgell et al. (2005), and Winkler et
al. (2006). Linearity of EPIDs for low MU deliveries has been attributed to the
ghosting effect, whereby charge carriers become trapped in defect levels. The
ghosting effect is examined in section 2.3.3. Comparisons of the dose response for
the EPID and ion chamber measurements were performed for 1 – 40 MU irradiations
(Budgell et al. 2005). The dose response of the EPID was determined from
evaluation of the central 50 x 50 pixels in the image. For both ion chamber and EPID
measurements, normalisation to a measurement of 100 MU was performed.
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Figure 2.3.2.1: Linearity comparison between the EPID and ion chamber for 6 and 8
MV photon beams for 1 – 100 MU irradiations (Budgell et al. 2005).

Ion chamber results demonstrate linearity within 2% for a 1 MU segment for both 6
and 8 MV beams. The ion chamber is used as a reference dosimeter with known
linear dose response behaviour for comparison with the EPID. EPID results
demonstrate a lack of linearity for low MU deliveries, in particular the results show
greater loss of linearity with an increase in beam energy. The decrease in EPID
signal for lower MU deliveries has been attributed to ghosting and image lag effects
by Budgell et al. (2005), Mail et al. (2005), Winkler et al. (2005) and McDermott et
al. (2006).
Winkler et al. (2006) performed an inter-comparison of 11 Elekta iViewGTTM aSiEPIDs. The panels were found to be non-linear with dose for MU deliveries less than
4 MU, with deviation of 5.5% for a 6 MV beam, and 7% decrease for a 25 MV
beam. For irradiations between 4 and 100 MU the linearity was found to be within
0.35% (Winkler et al. 2005). Deshpande et al. (2011) performed an inter-comparison
of three Siemens a-Si EPIDs with a variation of 2% between EPID and ion chamber
measurements down to a 1MU delivery.

The contribution of LINAC start-up fluctuations was also analysed by Winkler et al.
(2006), allowing a detector-only linearity analysis by elimination of LINAC
contribution. The linearity was found to improve to 3% for a 6 and 10 MV beam, and
20

3.5% for a 25 MV beam for the Elekta iViewGTTM panel for delivered MUs from 11000.

2.3.3 Ghosting and image lag
Ghosting and image lag occurs in EPID dosimetry due to the properties and
construction materials of each panel. Ghosting is the change of the EPID pixel
sensitivity to radiation due to trapped charges as a result of previous exposures to the
panel (McDermott et al. 2003) and can be attributed to a change in electric field
strength in the a-Si layer of the panel. This change in field strength creates a change
in sensitivity of the a-Si layer and hence image acquisition.
Image lag is the residual signal / charge from a measurement frame that was read out
or processed in subsequent image frames (i.e. the charge is read out in subsequent
frames, not the frame in which the charge was actually collected). This charge results
in an offset of the charge readout for the next reading/measurement made by the
panel (McDermott et al. 2003, Mail et al. 2007). In the first few acquisition frames
(following beam-on) no residual charge exists in the panel from previous
irradiations/previous frames. As acquisition continues, residual charge from previous
frames is trapped in the panel and builds until equilibrium is reached. Pre-irradiation
of the EPID is often performed such that the non-linearity associated with this
phenomenon is reduced (Budgell et al. 2005).

Numerous studies have been performed on all vendor EPID panels to assess the
effect of image lag and ghosting. An inter-comparison of the Siemens, Elekta and
Varian EPID panels by McDermott et al. (2006) demonstrated that all a-Si EPIDs
were subject to ghosting for small MU deliveries, with up to 5% variation when
examining EPID signal per MU.

Image lag and ghosting effects have been quantified by a two-image technique,
where the panel is irradiated with a small field, with an immediate irradiation of a
different sized field. A ratio is taken with another acquired image of the larger field
size without pre-irradiation. Studies have shown that ghosting accounts for a 1%
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difference in signal for Varian panels (Van Esch et al. 2004); a 1.6% difference was
found for Siemens panels (Nijsten et al. 2007).

Image lag and ghosting was investigated one step further using the two-field
technique for Elekta iViewGTTM panels as a function of time between irradiations of
the different field sizes, and with different MU irradiations of the fields (Winkler et
al. 2005). It was found that an increased dose delivered to the first field with
minimum time between subsequent irradiation caused an 8.9% difference in EPID
response.

Figure 2.3.3.1: EPID dose profile obtained for a 15x15 cm field with (solid line) and
without (dotted line) pre-irradiation of 500 MU in a 5x5 cm field. The ratio of dose
profiles is presented in the insert. (van Esch et al. 2004).

2.3.4 Segment-to-segment reproducibility
Budgell et al. (2005) examined the reproducibility of the EPID response for low and
fractional MU segments. The reproducibility was determined using a single IMRT
prescription containing up to 20 segments of 1 and 2 MU deliveries. An IMRT
prescription was used due to possible delivery differences between single exposures
and a clinical IMRT field.
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Table 2.3.4: Reproducibility for a 20 segment IMRT prescription including analysis
of the whole prescription and the last 15 segments (Budgell et al. 2005).

Greater variation was observed in the first 5 segments of the IMRT prescription
compared to the remaining measured segments. The variation was observed to be
reproducible with repeated panel irradiations. This was attributed to the start-up nonlinearity of the EPID caused by ghosting, and the initial ramp up of the LINAC.

2.3.5 Short-term and long-term reproducibility
Reproducibility of EPID panels has been examined for short-term and long-term
reproducibility with similar results obtained for all vendors.

Short term panel reproducibility was assessed over a set of repeated measurement
with an EPID panel in a single measurement session. Reproducibility was tested for
each of the different panels with the following maximum deviations from baseline
values established at the time of panel commissioning: Varian aS500 = 2.0% (Van
Esch et al. 2004), Elekta iViewGTTM = 0.5% (Winkler et al. 2005), Siemens Optivue
500/1000STTM = 0.7% (Nijsten et al. (2007). Deshpande et al. (2011) studied the
short term (10 consecutive measurements) and long term (12 month period)
reproducibility of 3 Siemens EPIDs with maximum 0.5% and 1.0% deviation from
baselines respectively.

2.3.6 Field size dependence
The change in output at the centre of a radiation field changes as a function of
irradiated field size. The variation in dose is the product of the phantom scatter factor
(Sp), the amount of scattered radiation contributing to dose from the amount of
phantom material irradiated, and the collimator scatter factor (Sc), the amount of
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scattered radiation resulting from the treatment head of the LINAC (measured using
a mini-phantom or ion chamber with build-up cap i.e. no phantom material present).

The change in output as a function of field size will differ to that of an ion chamber
in water due to the construction of the EPID and the non-water equivalence of the
materials contributing to different scatter conditions. These materials include metal
layers such as the Cu build-up plate, and the phosphor screen. These metal
components act to decrease the lateral scatter distance of the incident radiation
causing a decrease in penumbral width in comparison with a water phantom (Lee et
al. 2009), and cause an over-response to low-energy photons due to the photoelectric
effect of the high atomic number of the phosphor (Greer 2005). Gustaffson et al.
(2009) had previously investigated the effect of different materials used in EPID
panels on the resulting dose profiles and output factors obtained. It was found that
different materials had a profound effect on both profiles and output factors, leading
to the requirement that each panel must be characterised prior to use.

The EPID scatter factor (Spe) is equivalent to the phantom scatter factor described
above however it is the scatter contribution from the EPID panel (due to non-water
equivalent construction materials) measured as a function of field size. The EPID
scatter factor has been measured by Greer and Popescu (2003), Winkler et al. (2006),
Nijsten et al. (2007), Van Esch et al. (2007), and Deshpande et al. (2011) with a
maximum difference of 9% found between ion chamber measurements and the
EPID. The largest differences were observed in small field sizes, where a
considerable under-response of the EPID was measured.
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Figure 2.3.6.1: Field size response of 3 Siemens EPID panels with comparison to ion
chamber measured response for a (a) 6 MV and (b) 18 MV photon beams
(Deshpande et al. 2011).

2.3.7 EPID Detection methods
Current LINAC and EPID designs work on the detection of x-rays indirectly. Indirect
detection means that the x-ray is converted to light via a scintillator for detection by
the photodiode array. Various studies have been conducted to assess the suitability of
direct detection (x-ray detected without conversion to light) using the EPID.

Direct detection EPIDs were constructed by Vial et al. (2008) to create a water
equivalent panel for dose verification and comparison. For both 6 and 18MV the
direct detection panel gave equivalent doses to within 2% for both 6 and 10 MV
when compared to ionisation chamber measurements. The modified direct EPID
model provides water equivalent dose response but decreased image contrast due to
reduced contrast-to-noise ratios for the direct EPID.
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Figure 2.3.7.1: Comparison of normalised dose profiles (cross-plane) for 6MV flood
field exposures measured with direct and indirect detection EPIDs (corrected for
pixel sensitivity) and an ion chamber (Vial et al. 2008).

All properties of the EPID panel in response to radiation fields must be fully
understood and characterised before the imaging device can be implemented into a
radiotherapy department for quantification of dose and in particular for the QA of
IMRT fields.

2.4

IMRT / VMAT DOSE VERIFICATION QUALITY ASSURANCE

IMRT and VMAT plan verification is complex in nature. This complexity arises
from factors such as irregularly shaped and sized fields, the presence of small MU
segments, high dose gradients throughout the treatment fields and the off-centre
positioning of segments for IMRT treatments (Ezzel et al. 2003, ICRU report 83,
2010), with the added complexity of variable gantry speed, leaf speed, and variable
dose-rate for VMAT treatments (Bedford et al. 2009). As a result there has been
numerous studies looking at the optimum treatment measurement methods and
reporting criteria suitable for IMRT treatments. Measurement of IMRT fields in high
dose and low dose gradient regions have been recommended to be measured in a
similar fashion to 3DCRT treatments. However these methods (generally using a
point detector i.e. ionisation chamber) do not work optimally in regions of low doses
and high dose gradients (Palta et al. 2003, Mijnheer 2008).
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The most common method used for IMRT dosimetry is that of gamma analysis, first
devised by Low et al. in 1998. Gamma analysis involves the fusion of distance-toagreement (DTA) and percentage dose difference (%DD) criteria between a
reference dose plane and an evaluated dose plane. Typically the reference dose plane
is calculated and the evaluated dose plane is measured. The DTA searches a
specified area from a point in the reference plane to the evaluated plane to find the
closest point equal in dose. The %DD compares the dose at a point in the evaluated
plane to the corresponding point in the reference plane.

The gamma analysis

technique of dose comparison in highly modulated IMRT fields has been described
in a paper by Low et al. (2003), defining the gamma (γ) quantity as the minimum
difference in the renormalised multidimensional space between the evaluated
distribution and the reference point.

For a specific point in the reference plane, the dose distribution is searched in the
evaluated plane to locate the corresponding point. If the point is within a specified
distance to the reference point and within a specified percentage of the maximum
reference dose a pass or fail can be reported.

Figure 2.4.1: Geometric representation of gamma analysis dose evaluation criteria.
The dose difference and the distance to an agreement point is evaluated between the
centre of the sphere and the calculation point (Low et al. 1998).
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Basran et al. (2008) has stated clinical selection criteria for the gamma analysis
comparison of IMRT fields. A search distance or DTA of 3mm and dose difference
of 3% of the maximum dose is reported. These parameters are chosen due to the
increased need for plan delivery accuracy of the small, highly-modulated segments
of an IMRT field.

Variation of the required gamma analysis pass rate occurs between clinics for IMRT
plan approval. A widely accepted value of 90% of points passing the 3 mm, 3%
gamma criteria for all points that are above 10% of the maximum dose is employed
in many clinics (Antonuk 2002). Basran et al. (2008) states that a pass rate of 95% is
required for IMRT plan approval, with a lower 88% pass rate required for head and
neck cases. Variation in the pass rate of one treatment plan can arise from the type of
dose comparison used. The analysis of absolute dose is recommended in IMRT field
verification due to the combination of the intensity modulation and the dose output
over the entire field. It is possible when performing relative dose analysis to miss
significant errors in overall delivered dose to the entire field.

Ezzel et al. (2009) recommend caution is taken when using a per-field gamma
analysis for the sole verification of IMRT fields. A search area of 3mm in all
directions can decrease the detection efficiency of dose delivery error in a composite
IMRT field, when one or more individual segments may include delivery error but
the effect is undetected due to the large area available to find a point of dose
matching between reference and evaluated fluence maps. Nelms et al. (2011) tested
24 clinical head and neck IMRT cases with 4 different dose errors introduced.
Analysis was performed using gamma criteria of 3% / 3 mm, 2% / 2 mm, and 1% / 1
mm. Results provided information that common acceptance criteria for gamma
analysis of IMRT fields were not accurate in prediction of dose errors in a measured
plan. Gamma analysis is however, still widely used in the clinic to test delivery of
IMRT beams compared with the treatment plan due to the ease of comparison of
doses and the ability see areas that fail different criteria set by the user.

As a result of the complex nature of IMRT and VMAT treatment beams, twodimensional verification of planned and measured planar dose maps is required for
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field comparison. Two-dimensional detectors such as film (radiographic and
radiochromic), ion chamber arrays, diode arrays and EPIDs are commonly
recommended and used to verify IMRT fields (Ezzel et al. 2002, ESTRO Booklet 9
2008, ICRU Report 83 2010, ASTRO practice guideline for IMRT 2011). Phantoms
using multiple planes of detectors such as the Scandidos Delta4 diode array
(Scandidos, Uppsala, Sweden) have also been produced for the verification of
VMAT in order to provide 3D reconstructed measured dose distributions for
comparison with planned doses.

2.4.1 Quality Assurance using Film
Radiographic film has frequently been employed to verify IMRT fluence maps by
obtaining a two-dimensional dose distribution of a given radiation field (Olch 2002).
The high spatial resolution of radiographic film provides accurate dose reporting
over the entire field of view for the treatment area. Zhu et al. (2002) reports a
maximum 2 mm difference between film measurements and those obtained with an
ion chamber in a scanning water phantom in high dose gradient regions. In low dose
gradient areas, a maximum difference of 1% was observed.

The introduction of radiochromic film into the market has seen an increase in the use
of film for dosimetry and for pre-treatment verification of IMRT. Extensive literature
exists examining properties of radiochromic film and applications for its use. The
AAPM Task Group 55 provide recommendations on radiochromic film dosimetry
(Niroomand et al. 1998), however this report does not include the newer film types
that have improved performance as dosimeters. Radiochromic film dosimetry for
radiotherapy beams is appealing due to its high spatial resolution, energy
independence in MV energies (Butson et al. 2009), tissue-equivalence (ISP 2009),
and due to the self-developing nature of the film. Radiochromic film has
subsequently been used for IMRT dose verification QA (Ziedan et al. 2006, Chung
2009, Kairn et al. 2011) with gamma analysis results for film dosimetry matching
that of other detectors.
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Film measurements for IMRT and VMAT dose verification QA are complex due to
the delayed nature of read-out and technical difficulties to accurately convert the
optical density of the film to absorbed dose, and potential difficulties associated with
flatbed scanners (scatter, positioning and polarisation).

2.4.2 Quality Assurance with Ion Chamber / Diode Arrays
Arrays of ion chambers and diodes are commercially available and frequently used
for clinical IMRT and VMAT dose verification QA. The array is advantageous due
to the accuracy of dose reporting by the use of ion chamber measurements, and the
ability to measure an entire treatment field due to multiple chambers present within
the device. Studies previously undertaken with ion chamber arrays show that there is
a limit to the accuracy of fluence map reporting due to the spatial separation of the
individual ion chambers (Amerio et al. 2004, Spezi et al. 2006, Tyler 2008).

Methods to increase the sampling capabilities of the arrays for use in highly
modulated and complex IMRT fields have been developed by Spezi et al. (2006) and
Tyler (2008). Implementation of these methods are time consuming and require
movement accuracy well within 0.5 mm and software manipulation and summation
of multiple measured data to obtain a higher resolution fluence map for accurate
comparison. As a result the array and summation methods would not be suited for
clinical IMRT dose verification.

2.4.3 Quality Assurance using the EPID
The number of patients prescribed IMRT radiotherapy for treatment of their cancer
has increased rapidly in Australia over the past few years with 6.5% of new
radiotherapy courses being treated using the technique in 2010 (RANZCR 2011).
Following the introduction of the technique at the Prince of Wales Hospital in 2006,
and at Liverpool Cancer Therapy Centre in 2008, patient loads have increased,
causing an increased strain on resources and time due to patient specific QA routines
used. Therefore there is a need for a fast, more efficient IMRT dose verification QA.
The EPID has been suggested as a solution due to the ability to collect and analyse
information in real-time, with no additional time for equipment setup required.
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The use of EPIDs for QA and IMRT dose verification has been increasing in the
previous few years. Publications by Budgell et al. (2005) and van Elmpt et al. (2009)
discussed the use of the EPID for regular IMRT dose verification QA. The method of
pre-treatment QA is described as fast and therefore beneficial in clinics with high
patient-throughput. In the IMRT dose verification QA method, a simple ‘dummy
run’ of the treatment is performed with no phantom or patient in the beam. The
planar dose maps are collected by the EPID and then used for online, automated
comparison with the TPS. The ability for the EPID to detect MLC positioning errors,
incorrect data transfer of the treatment plan, and errors in the treatment delivery,
make the EPID a favourable online dosimetric tool for routine clinical QA and for
IMRT dose verification QA methods (Clarke and Budgell 2008).

Review of various approaches to EPID dosimetry for IMRT and VMAT dose
verification QA, and methods currently used are discussed in section 2.5.

2.5

IMRT VERIFICATION USING EPIDs

Different methods have been derived and used in practice for the verification of
IMRT fields with EPIDs. These methods are based on EPID measurements with
pixel-to-dose conversion, modelling of predicted EPID fluences and by Monte-Carlo
simulations.

Currently, two commercial systems exist for EPID dose verification QA EPIDose
(Sun Nuclear Corporation, Florida, USA), and Varian Portal Dosimetry (Varian
Medical Systems, Palo Alto, USA). These systems use algorithms to calculate the
EPID predicted dose for a radiation field and compares them to the radiation field
measured with the EPID. The EPID image can also be imported into the software and
converted to dose for analysis and comparison with a TPS planned fluence.

Independent IMRT and VMAT dose verification QA methods have been developed
by a number of people using different EPID models and vendor types. Most methods
employ complex post-processing corrections applied to the EPID image to account
for the panel characteristics such as off-axis and field size corrections described
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previously. Two methods have been developed; transmission methods (with a patient
or phantom between the source and the EPID) (Partridge 2002, McDermott et al.
2007, Nijsten et al. 2007, Mans et al. 2010, and Pecharromán-Gallego et al. 2011)
and non-transmission methods (without a patient or phantom between the source and
the EPID) (Grein 2002, Siebers et al. 2004, Van Esch 2004, Greer et al. 2007, Nijsten
et al. 2007(b), Lee et al. 2009). The TPS has been used by Khan et al. (2008) to
produce an EPID dose model that simulates the measured field on the EPID for
planned IMRT fields and allows a comparison between measured EPID and
modelled EPID 2D fluences.

2.5.1 Transmission methods
Transmission methods involve measurement of the photon fluence with the EPID
with an object (phantom or patient) between the emitted photon beam and the panel.
Numerous studies have been presented using the transmission methods to measure
the photon fluence for IMRT beams in-vivo or using a phantom for pre-treatment
verification using back-projection algorithms to project the EPID measured dose
back into a phantom or onto the patient CT scan for comparison with planning data.

McDermott et al. (2007), Mans et al. (2010) and Pecharromán-Gallego et al. (2011)
have presented transmission QA techniques that use the measured EPID image and
in-house back-projection techniques to calculate the EPID dose onto a phantom.

Pecharromán-Gallego et al. (2011) has similarly used back-projection on EPID
measurements. A model based on measurements performed to assess the
characteristics of the EPID was established by the group, with this model used to
project the patient doses based on the beam shapes onto the patient plan. The model
included beam hardening and off-axis effects of the panel. It was established that the
model could be used for clinical verification of IMRT and showed high gamma
passing rates.

Mans et al. (2010) utilised a back-projection technique to reconstruct in-vivo
measured EPID doses at a plane parallel to the panel at the level of the isocentre. The
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back-projection algorithm incorporates the panel scatter properties, the inversesquare law, and attenuation of the radiation beam between the exit of the radiation
from the patient or phantom to the plane of reconstruction. Multiple reconstruction
planes can be calculated with a 3D dose calculated for the patient treatment.

McDermott et al. (2007) used the EPID images back-projected into a slab phantom to
compute the agreement (using gamma analysis) between measured and planned
prostate IMRT plans. EPID doses were compared to radiographic film with over 98%
agreement found when compared to the EPID.

The above-mentioned transmission measurements can use a convolution approach to
convert the measured EPID fluence to a dose distribution in a homogenous phantom.
The convolution method uses a scatter kernel applied to the measured fluences to
account for the differences in the scatter conditions of the EPID compared to a
homogenous water phantom.

Convolution techniques have been presented by a number of authors. These
convolution kernels are applied to fluences generated in the TPS for comparison to
the EPID measured fluence map, or conversely, applied to the measured dose map to
match the TPS generated dose distribution.

2.5.2 Non-transmission methods
Non-transmission methods involve measurement of a fluence using the EPID with no
object between the detector and the source of photons (treatment head). Previous
studies have used this method for comparison of pre-treatment measured fluences
(with the EPID), to planning system-generated fluences.

Siebers et al. (2004) used non-transmission measured EPID fluences and Monte
Carlo calculations to reconstruct a 2-D dose plane at the level of the detector. The
EPID geometry was modelled using Monte Carlo simulations and applied to the
measured fluences to account for the different materials and densities within the
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panel. An IMRT test field was used with 99% of points passing gamma analysis with
2%, 2mm criteria.

An approach by Van Esch et al. (2004) used measured EPID fluences of open fields
to modify a dose calculation algorithm in a commercial TPS (Varian Cadplan) to
predict the portal dose distribution obtained for treatment fields with the EPID. The
use of EPID measurements for beam data acquisition effectively eliminated any postprocessing scatter kernel corrections due to non-homogeneity. The predicted portal
dose image (PDI) was obtained using the TPS for generation of PDIs for IMRT
treatment fields. PDIs were exported and directly compared to measured EPID
fluences with 3%, 3mm agreement between PDI and measured EPID fluences. Other
studies have used this method of PDI generation for EPID IMRT dose verification
QA with high gamma analysis agreement rates (Warkentin et al. 2003 and van
Zijtveld et al. 2006). This method does not reflect the actual dose to the medium
(water) when the fluence is compared to planning system dose fluences, and relies on
the correct application of a scatter convolution kernel (simulated by Monte Carlo
methods) for accurate results.

Chytyk et al. 2009, 2013 developed a model to predict the EPID fluence at the level
of the panel for measured EPID fields. The model was used to calculate the predicted
EPID fluences with those physically measured with an EPID for 20 IMRT plans with
a mean of 96.6% of pixels passing the gamma criteria set of 2%, 3mm.

A simplified approach to IMRT dose verification QA with a direct comparison from
EPID to dose at an equivalent depth in a water phantom was presented by Lee et al.
(2009). The aim of the approach was to create a simple pre-treatment verification for
IMRT plans, where the plan is delivered to the EPID (using non-transmission
methods) and compared to the TPS. EPID measurements were also compared to
measurements obtained with a two-dimensional diode array (MapCHECK®, Sun
Nuclear Corporation, Melbourne, FL) and with radiographic film, showing good
agreement between the EPID image, the TPS and other dosimetry methods (Lee et al.
2009). The work presented by Lee et al. (2009) was performed for Varian EPIDs

34

only. The research presented in this thesis is based on the work of Lee et al. (2009),
and applied to other vendor systems and treatment techniques.

EPID images were obtained for different field sizes and compared to ionisation
chamber measurements at different depths in water. An equivalent depth was found
where the output factors for the EPID matched that in water. Profile comparisons
were then made with an off-axis correction applied to the EPID. A calibration of
EPID pixel value to dose was then performed before verification and testing of
IMRT fields.

Figure 2.5.2.1: Change in dose resulting from a change in MLC field size for a
Varian as500 EPID: (a) comparison to dose reported for an ion chamber at different
depths on the beam CAX, (b) comparison to dose reported for an ion chamber at d=5
cm in water on the beam CAX (Lee et al. 2009).

An equivalent depth of 5cm was determined for the 6 MV and 3 cm for an 18 MV
beam between EPID and ion chamber measurements for field size factor
comparisons. These reference depths were then used for application of an off-axis
ratio to the EPID image for treatment field verification, with the off-axis ratio values
being derived from ion chamber profiles at the reference depth in a water phantom.
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The central 9 x 9 pixels of a 100 MU reference 10 x 10 cm2 field size measured by
the EPID were averaged and converted to absorbed dose using a pixel to dose
calibration factor. The calibration factor was calculated using the ionisation chamber
dose measured at the EPID equivalent depth in water for 6 and 18 MV.

Fcalibration 

Doseionchamber,dref ,10 x10 cm,100 cmSAD (cGy)
PixelEPID ,10 x10 cm ,SSD

(2.5.2)

Using the calibration factor to convert EPID pixel values to dose, more complex
treatment fields and patient IMRT treatment plans were compared between EPID and
TPS generated dose planes at the reference depth (equivalent depth in water).

EPID measured profiles were compared with measurements obtained with
radiographic film and the MapCHECK® device. Comparisons and analysis were
performed using gamma analysis criteria of 3 %, 3 mm with a 10% of maximum
dose threshold. Agreement between the TPS and the EPID for IMRT dose
verification was 97.0 ±0.3 % for a prostate plan and 97.5 ± 1.8 % for a tonsil plan
using 3 %, 3 mm gamma criteria. The method produced by Lee et al. (2009) is
effective in producing a relatively simple IMRT dose verification process using an
EPID.

2.5.3 EPID modelling using the TPS
Khan et al. (2008) used the Pinnacle3 treatment planning system (Philips Medical
Systems, Madison, USA) to model the Varian aS500 EPID response to 6 MV photon
beams. Open square and rectangular fields were measured with the EPID, using the
measured EPID profiles and output factors to create a 6 MV EPID beam model in the
TPS. This beam model was used on patient clinical IMRT plans to predict the
fluence measured by the aS500 EPID for pre-treatment dose verification QA. This
method provided gamma analysis agreement >95 % using 3 % / 3 mm criteria for all
measured fields and eliminated the need for complex scatter corrections of the
measured EPID image.
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The requirement for fast, accurate verification of IMRT fields using a simple vendorindependent model forms the basis of this work. The requirement for accurate
gamma analysis when comparing measured and planned doses is also studied with
varying degrees of modulations added into fields to determine the usefulness of
gamma analysis in IMRT and VMAT dose verification QA.
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3 MATERIALS

This research project involved the use of materials and equipment in the radiotherapy
department including LINACs, amorphous silicon EPIDs, a commercially available
two-dimensional diode array, treatment planning software and point dosimeters.

3.1

LINEAR ACCELERATORS AND EPIDS

Most modern LINACs are standard equipped with an EPID for patient imaging.
EPID designs are different between vendors and as a result, panels for a Siemens
Oncor ImpressionTM (Siemens Medical Solutions Erlangen, Germany) and an Elekta
AxesseTM (Elekta CMS Crawley, UK) LINACs were characterised for dosimetry.

3.1.1 Elekta AxesseTM LINAC and iViewGTTM a-Si EPID
An Elekta AxesseTM LINAC equipped with a Beam Modulator (BM) treatment head
was used for measurements. The AxesseTM at the Prince of Wales Hospital is a dual
mode LINAC with maximum nominal energies of 10 MV X-rays and 18 MeV
electrons.

The BM MLC replaces both collimator jaws with an 80 leaf MLC. The BM has a
maximum field size of 16 x 21 cm, and a 4mm leaf width projected at the isocentre.
The BM is capable of full interdigitation of the leaves across the 21 cm field width.
Due to the limitations of the MLC size, the BM is not able to create a 10 x 10 cm2
field size, hence a 10.4 x 10.4 cm2 field is used as the reference field size for this
LINAC.
An iViewGTTM a-Si EPID (Perkin-Elmer number XRD 1640 AG5) is attached to the
rotating gantry of the AxesseTM by a motorised arm directly beneath the treatment
head and perpendicular to the delivered treatment beam. The motorized arm is used
to extend and retract the EPID for patient imaging before or during treatment.
Motorised retraction is essential to minimize radiation damage to the electronics
surrounding the flat panel that may be induced as a result of large treatment field
sizes irradiating the panel area and surrounds.
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The EPID has an active detection area of 41 x 41 cm2 at 160 cm SSD, projecting to
25.65 x 25.65 cm2 at the level of the machine isocentre. The active detection area
consists of 1024 x 1024 detector elements with a pitch of 0.4 mm. The EPID has a
fixed SSD of 160 cm available for imaging. The iViewGTTM acquires images as
frames where a frame is a complete readout of the detector area. The iViewGTTM has
a frame acquisition rate of 320 ms (3.1 frames per second).

Figure 3.1.1: Elekta AxesseTM linear accelerator and iViewGTTM EPID at the Prince
of Wales Hospital.

3.1.2 Siemens PrimusTM/OncorTM LINAC and OptiVue 1000STTM a-Si EPID
Two Siemens LINACs at the Prince of Wales Hospital were used in this research
project. The Siemens PrimusTM and Siemens Oncor ImpressionTM LINACs are dual
mode LINACs with clinical operating maximum nominal energies of 10 MV X-rays
and 21 MeV electrons. Each machine is capable of treatment options from 3D
Conformal Radiation Therapy (3DCRT), to IMRT and IGRT.
The PrimusTM and OncorTM have different MLC configurations. The PrimusTM has
29 opposed leaf pairs. The outer two leaves have a leaf projection of 6.5 cm at the
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isocentre plane, with the inner 27 leaves having a projection of 1 cm. The Primus
LINAC MLC design retains the use of the upper collimator jaw and replaces the
lower collimator jaw with the MLC. The leaf-ends are flat and double-focused on the
x-ray source so that the leaf-ends and sides align with beam divergence in one
dimension (1D) (Metcalfe et al. 2007).
The OncorTM is equipped with a 160 leaf MLC consisting of 80 opposed leaf pairs.
Each leaf is of the same width and has a projection of 4 mm at the isocentre. The
Oncor LINAC MLC design also retains the use of the upper collimator jaw and
replaces the lower collimator jaw with the MLC.

Both Siemens LINACs are able to achieve a 40 x 40 cm field size at isocentre, with
the MLC leaves allowed to travel from a fully retracted position to 10 cm across the
beam central axis on the PrimusTM (Klien et al. 2001), and to 20 cm across the
central axis on the OncorTM.
OptiVue 1000STTM AMFPI EPIDs (Perkin-Elmer number XRD 1640 AG9) are
attached to the gantry of the LINAC on a motorised arm directly beneath the
treatment head. The motorized arm is used to extend and retract the EPID for patient
imaging before or during treatment. Positioning accuracy of 2 mm and repeatability
of 1 mm for the EPID is reported by Siemens Medical Solutions (2007) for the
robotic arm.
The EPID is an a-Si detector (like the Elekta iViewGTTM) and has dimensions of 672
x 599 mm with an active detection area of 41 x 41 cm2 at 160 cm SSD, projecting to
25.65 x 25.65 cm2 at the level of the machine isocentre. The active detection area
consists of 1024 x 1024 detector elements with a pitch of 0.4 mm. A spatial
resolution of 0.41 line pairs per mm has been reported by Siemens (2007). The
OptiVue 1000STTM acquires images as frames where a frame is a complete readout
of the detector area. The OptiVue 1000STTM has a frame acquisition rate of 143 ms
(7.0 frames per second).
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Different source-to-detector distances of the EPID can be achieved with the Siemens
panels. Movement and positioning for detection is allowed in the range from 115 cm
SSD to 160 cm SSD. At the Prince of Wales Hospital for LINAC QA and patient
imaging, the EPID is used at a distance of 145 cm SSD.

Figure 3.1.2: Siemens Oncor ImpressionTM linear accelerator and OptiVue
1000STTM EPID at the Prince of Wales Hospital.

3.2

DOSIMETERS

3.2.1 Ionisation chambers
Various ionisation chambers were used in this research to validate each EPID panel
for use as a reliable dosimeter for radiotherapy beams.
Small volume CC04 (0.04 cm3 inner volume) and CC13 (0.13 cm3 inner volume)
thimble ionisation chambers (Scanditronix-Wellhöfer, Schwarzenbruck, Germany)
were used for measurement of output factors and field profiles. The CC04 ionisation
chamber was used for all field sizes less than 4 x 4 cm2 due to volume effect
limitations of larger ion chambers in these smaller fields (Laub and Wong 2003, Das
et al. 2008).
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A Farmer-Type NE 2571 thimble ionisation chamber was used for EPID scatter
factor determination. This chamber was used due to the use of a mini-phantom with a
fixed insert for the NE 2571 chamber for Sc measurements. The NE 2571 chamber
has a 0.6 cm3 inner volume with graphite wall and central electrode (IAEA TRS-398
2004).

3.2.2 MapCHECK® 2D diode array
The verification of high dose gradient fields requires detectors that are sufficiently
small enough to limit the volume effect on measured fields and segments (Laub and
Wong 2003, Cadman et al. 2005).

At the Prince of Wales Hospital, a MapCHECK® two-dimensional diode array is
used for routine pre-treatment IMRT delivery verification. The MapCHECK® has a
detection area of 22 x 22 cm2, with 445 diodes encased at an equivalent water depth
of 2cm from the detector surface. Each diode is 0.8 x 0.8 mm2 in size, with 7.07 mm
spacing between adjacent diodes in the central 10 x 10 cm2 and 14.04 mm spacing in
the area outside the central 10 x 10 cm2 region.

Figure 3.2.2.1: Detector spacing diagram for the MapCHECK® diode array (from
manufacturers website).

The MapCHECK® array is used at the machine isocentre perpendicular to the
treatment beam with all IMRT and VMAT beams set to have Gantry = 0°. This
nominal gantry angle is used due to the angular dependence of the diodes in the 2D
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array. Fluence maps for each IMRT and VMAT beam are measured with the
MapCHECK® in absolute mode and compared against TPS generated fluences. A
gamma analysis criteria of 3% / 3mm is routinely used with a 95% compliance rate
required for plan approval.

3.3

PHANTOMS

3.3.1 Solid Water
A Solid WaterTM (PTW RW3) phantom was used as build-up and backscatter
material. By weight the PTW RW3 consists of carbon (67.22%), oxygen (19.84%),
hydrogen (8.09%) and chlorine (0.13%). The solid water slabs have an effective
atomic number of Z = 5.96 and have an electron density similar to water (1.012)
rendering them water and tissue equivalent for photon beams up to 25 MV
(Constanitinou 1982).

3.3.2 Perspex Mini-Phantom
A cylindrical Perspex mini-phantom was used for collimator scatter factor (Sc)
measurements. The phantom was fabricated in-house, with a diameter of 4 cm and a
length of 20 cm. A hole for the ionisation chamber was created in the phantom so
that the ionisation chamber effective point of measurement (peff) was at a depth of 10
cm.

Figure 3.3.2.1: Construction of perspex mini-phantom used for collimator scatter
measurements.
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3.3.3 3D scanning water tank
Dose profiles were measured using an ionisation chamber in the Blue Phantom
scanning water tank (Scanditronix-Wellhöfer, Schwarzenbruck, Germany). Using
this phantom, profiles could be obtained in the cross-plane and in-plane at different
depths using an ionisation chamber or diode.

Figure 3.3.3.1: Scanditronix-Welhoffer Blue Phantom 3D scanning water tank used
for measurement of beam profiles.

3.4

TREATMENT PLANNING SYSTEMS

Treatment planning systems (TPS) were used in this research to create QA plans for
IMRT and VMAT patient treatments for verification with EPID measurements. The
TPS was used to generate a QA plan on a water phantom at a reference depth (choice
based on output factor measurements). Each QA beam was calculated on the
phantom and a two-dimensional dose fluence map was exported at the reference
depth for gamma analysis comparison with EPID measured fluence for the IMRT
beam.

44

Figure 3.4.1: Patient IMRT plan (left) with beams calculated on a water phantom
for IMRT QA plan generation (middle) and 2D planar dose export at the reference
depth (right).

3.4.1 XiO®
The XiO® Treatment Planning System v4.64 (Elekta AB, Stockholm, Sweden) was
used for the planning of conformal and IMRT fields in this project. XiO® is capable
of 2D and 3D treatment plans including MLC-based IMRT, brachytherapy and
proton therapy treatments. At Liverpool Cancer Care Centre and the Prince of Wales
Hospital, this planning system is used for 3D conformal and IMRT treatment
planning.

Beam calculation methods of Fast Fourier Transformation (FFT) convolution, Pencil
Beam, Multi-Grid Superposition and Fast Superposition can be employed by XiO®
for calculation of absorbed dose in a patient or phantom. The chosen calculation
method depends on the beam characteristics (photons or electrons) and the
parameters of interest to the physicist (Mackie et al. 1997). Multi-Grid Superposition
is the algorithm used at the Prince of Wales Hospital and Liverpool and Macarthur
Cancer Therapy Centres for patient photon beam calculation. As a result, this method
was used for beam calculation in this thesis.

XiO® was used to generate a virtual water cube phantom with photon beams placed
perpendicularly onto one of its faces. 2D dose distributions (fluences) for open and
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modulated fields were extracted at different depths (perpendicular to the beam axis)
and exported for analysis.

3.4.2 Monaco®
Monaco® v 3.10 (Elekta AB, Stockholm, Sweden) was used for the calculation of
patient IMRT plans onto a water phantom at reference depths dependent on the
treatment beam energy. Monaco® is a dedicated IMRT and VMAT planning system
that uses Monte Carlo algorithms for dose calculation and segmentation of IMRT
patient plans.
A Solid WaterTM phantom measuring 30 x 30 x 30 cm3 was imaged with the CT
scanner and imported into Monaco® for IMRT QA calculations. A physical phantom
was required due to an inability of Monaco® to calculate dose onto a virtual
phantom. The phantom electron density was overridden to a relative electron density
of 1.00 for all IMRT QA calculations, following department protocol.

3.5

SOFTWARE ANALYSIS TOOLS

3.5.1 Matlab® R2010a
Matlab® R2010a (The Mathworks Inc, USA) was used as an image analysis tool in
this thesis. The program is a comprehensive mathematical tool using matrices for
data processing. A Graphical User Interface (GUI), array operations and matrix
algebraic operations allow the program to be a useful tool in radiotherapy physics for
solving imaging and dosimetry problems.

Matlab® R2009a was used in this thesis to extract information and perform
manipulations on acquired EPID images and allow comparisons with TPS and other
measured data.
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3.5.2 RIT v5.4
RIT v5.4 (Radiological Imaging Technology Inc, Colorado Springs USA) is a
commercial image analysis program specifically designed for use in radiotherapy.
RIT v5.4 was used for the import and analysis of IMRT EPID images from the
iViewGTTM and OptiVue1000STTM using vendor-specific image import functions.
An IMRT routine is be used to evaluate the matching of measured and planned
IMRT fluences in both absolute and relative modes.

Figure 3.5.2.1: Gamma analysis result window for an IMRT field showing (from top
left) absolute dose difference, calculated gamma map, pixel histogram and 3D
absolute dose difference map (Obtained from RIT website).

For the purposes of this research project, measured IMRT fluences with the EPID
were imported into RIT v5.4 for comparison with planned fluences from XiO®.

3.5.3 OmniPro I’mRT
This software is a commercially based system designed to accompany the MatriXX
I’mRT 2D ionisation chamber array. The OmniPro I’mRT (IBA-Dosimetry AB,
Sweden) is an analysis tool for planned and measured doses, incorporating gamma
analysis, dose difference, and DTA routines for comparison of data. The software
was developed for use with the MatriXX array, radiochromic film and commercially
available EPIDs (via DICOM import).

Two-dimensional plan verification can be performed in OmniPro I’mRT between a
measured data set and a planned dose data set. An illustration of the 2D plan
verification workspace is presented in Figure 3.5.3.1: the upper left window is
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displaying a measured fluence map (measured with the MatriXX array), the lower
left window shows the planned dose fluence map for the radiation field. Analysis
tools are shown in the right hand side of the workspace with dose profile comparison
shown in the top pane and a 2D gamma analysis map shown in the lower pane.

Figure 3.5.3.1: Screen shot of the IMRT comparison window on OmniPro I’mRT
software with (clockwise from top-left) measured fluence, profile comparison
between measured and planned doses, gamma analysis map, and planned fluence
from XiO®.

The OmniPro I’mRT software was used in this research project for comparison of
modulated EPID fields with planned doses due to the capacity to make rapid gamma
criteria changes.
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4 METHODS
All data acquired with the Elekta iViewGTTM and the Siemens OptiVue 1000STTM
EPIDs were frame-averaged (image pixel values displayed in the image are the
average pixel values for the whole radiation [over a multiple frame acquisition]),
flood field corrected images. Frame–averaged images display the average EPID pixel
value for an acquired number of frames for an irradiation. The integrated image was
calculated from the frame-averaged image by multiplying the pixels by an inverse of
the number of frames, the ‘FramePixelFactor’ which is a parameter included in the
log file for Elekta acquired images and the number of frames found in the DICOM
head of the Siemens acquired images.
All EPID measurements were performed at 160 cm SSD for the Elekta iViewGTTM
and at 145 cm SSD for the Siemens OptiVue 1000STTM.

4.1

REPRODUCIBILITY

The short term reproducibility of the Elekta iViewGTTM and the Siemens OptiVue
1000STTM EPID panel were determined using repeat irradiations of the panel in a
single session and evaluating the percentage standard deviation in average pixel
value at the centre of the field.

4.2

LINEARITY

A linear detector response with delivered dose is a desirable characteristic for a
radiotherapy dosimeter (Kahn 2010). The Elekta iViewGTTM and the Siemens
OptiVue 1000STTM EPID panel response with delivered absorbed dose was
calculated independently of the LINAC (eliminating start-up effects) by performing
simultaneous measurements with an ionisation chamber. The linearity of the EPID
panel, independent of the LINAC was calculated using equation 4.2 and was
expressed as a percentage deviation from unity:

=
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,
,

)
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/
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,
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)
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(4.2)

Where R(EPID, MU) is the EPID response to a delivered number of monitor units
(MU), R(EPID, 100MU) is the EPID response to a delivery of 100 MU, and similarly
R(ion chamber, MU) is the ion chamber response to a delivered number of MU, and
R(ion chamber, 100MU) is the ion chamber response to a delivery of 100 MU.

4.2.1 EPID measurements
A 10.4 x 10.4 cm2 field and a 10 x 10 cm2 were exposed onto the flat panel for the
Elekta and Siemens LINACS respectively. Exposures of 1 – 200 MU were measured
for 6 and 10MV with the mean pixel value in the central 10 x 10 pixels of the panel
(corresponding to a 0.4 x 0.4 cm2 region of interest at the beam central axis)
calculated for each exposure and normalised to the mean pixel value calculated for
the 100 MU exposure.

4.2.2 Ionisation chamber measurements
Ion chamber measurements were performed at the same time as EPID acquisition to
account for any ramp-up effects of the LINAC. The integrated charge (in nC) was
collected for each exposure using a Farmer Type NE2571 (S/N: 2721) at a depth of
10 cm in a RW3 solid water phantom at 100 cm SSD. The integrated charge for each
exposure was normalised to the collected charge for the 100 MU exposure.

The EPID linearity, independent of the LINAC, was calculated for each panel for 6
and 10 MV beam energies by taking the ratio of the EPID normalised response with
the ion chamber normalised response for each exposure.

4.3

FIELD SIZE DEPENDENCE

The absorbed dose in a material from a radiation beam changes as a function of
irradiated field size. As the size/area of the radiation beam becomes larger, there is
an increase in absorbed dose (in cGy per MU), on the beam central axis. This
increase is a result of a larger amount of scattered radiation from the collimator
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surface produced in the phantom material from the larger area/volume irradiated
(Podgorsak 2005).

4.3.1 EPID measurements
To characterise the phantom scatter contribution from the EPID (due to non-water
equivalent composition), field size response measurements were performed on each
EPID for 6 and 10 MV. Integrated images were acquired for field sizes varying from
2.4 x 2.4 cm2 up to 16 x 16 cm2 for the Elekta iViewGTTM and 2 x 2 cm2 to 22 x 22
cm2 for the OptiVue1000STTM. The 16 x 16 cm2 maximum field size was used for
the Elekta due to the maximum field size constraint of 16 x 21 cm. The average value
in the central 10 x 10 pixel region for each field size was normalised to the average
value in this region for the reference field size (10.4 x 10.4 cm2 for Elekta and 10 x
10 cm2 for Siemens).

4.3.2 Ion chamber measurements
The integrated charge on the beam central axis (CAX) was collected using a small
volume CC04 (S/N: 4524) ionisation chamber (IBA Dosimetry GmbH, Germany) in
a Solid WaterTM RW3 phantom at 100 cm SSD for all EPID measured field sizes.
The integrated charge for each field size was normalised to the charge collected for
the 10.4 x 10.4 cm2 and 10 x 10 cm2 with the Elekta and Siemens LINACs
respectively. Ionisation chamber measurements were performed at different depths in
1 cm increments in the RW3 phantom to determine a reference depth in water (dref)
at which the EPID scatter properties effectively match that of the ion chamber. Ion
chamber measurements were performed multiple times both within and between
sessions (n  9).

A quantitative comparison between the EPID and ionisation chamber measurements
at each depth was provided by calculating the sum square of differences between
normalised EPID data and normalised ionisation chamber responses at different
depths in water. The depth of the ion chamber that returned the smallest difference
between the ionisation chamber and EPID responses was defined as the EPID dref.
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4.3.3 Treatment Planning System verification
To verify the accuracy of measured ionisation chamber field size responses, beams
used for field size measurements from the Elekta and Siemens LINACs were created
and placed onto a virtual water phantom in the XiO® TPS (Elekta AB, Sweden) at
the previously determined dref . The virtual phantom dimensions were 40 x 40 x 40
cm3 with each beam MU matching that used for measurements (100 MU per beam).

The central axis dose (in cGy) was calculated by the TPS on the CAX at the
reference depth for each field size and normalised to the dose for the 10.4 x 10.4 cm2
and 10 x 10 cm2 reference field sizes. TPS-generated output factors were then plotted
as a function of field size and compared to the ionisation chamber and EPID data.

4.4

EPID SCATTER FACTOR MEASUREMENTS (Spe)

To determine the contribution of the EPID panel scatter to the total scatter / field size
response, the collimator scatter factor (Sc) for each LINAC was measured. The total
scatter (Scp) response for the Elekta and Siemens EPIDs at 6 and 10MV was
measured in Section 4.3. The Scp is a composite measurement of Collimator Scatter
(Sc) and Phantom Scatter (Sp) for the same field size:

S cp ( FS )  S p ( FS )  S c ( FS )

(4.4.1)

Collimator scatter includes photons scattered by all components of the LINAC head
in the path of the treatment beam. Sc changes as a function of field size due to the
amount of LINAC collimator and flattening filter ‘seen’ in the field.

Phantom Scatter is the component of the measured dose at a point that results from
scatter in the phantom material, this is directly related to the amount of phantom
irradiated. This Sp value is independent of the collimator scatter contribution.
Quantification of the phantom scatter component for the EPID (Spe) was determined
by dividing the field size response of the panel (Scp,e)(FS) with the measured Sc(FS)
for each LINAC and energy:
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S pe ( FS ) 

S cp ,e ( FS )
S c ( FS )

(4.4.2)

By calculating the Spe for each panel it was possible to determine the internal scatter
properties of the a-Si EPID and assess any effect on dosimetry. It has been well
documented that due to the internal structure of the panel, the EPID will not be water
equivalent due to the presence of silicon, phosphor, and metal layers (Deshpande et
al. 2011).

4.4.1 Collimator Scatter, Sc measurements
A Perspex Mini-phantom was used for measurements as recommended by ESTRO
Booklet 3 (1998). This mini-phantom was 4 cm in diameter and allowed a Farmer
type NE 2571 (S/N: 2721) chamber to sit with the effective point of measurement
(peff) at a depth of 10 cm from the surface. For Sc measurements to be accurate, the
field size must fully encompass the mini-phantom (AAPM TG75).

Measurements were performed at an SSD that matched the EPID SSD field size
factor measurements. Field sizes were measured from 4 x 4 cm2 up to 16 x 16 cm2
for the Elekta iViewGTTM (160 cm SSD) and 5 x 5 cm2 up to 22 x 22 cm2 for the
Siemens OptiVue 1000STTM (145 cm SSD). Field sizes smaller than those stated
could not be physically measured due to the dimensions of the mini-phantom;
however, they could be extrapolated from the larger field size measurements.

The charge collected with the ionisation chamber was normalised for each field size
to the collected charge obtained for the 10.4 x 10.4 cm2 and 10 x 10 cm2 field sizes
for the Elekta AxesseTM and Siemens OncorTM LINACs respectively. The normalised
data was plotted as a function of field size, with a polynomial trend-line fitted.
Extrapolation of the data to the smaller field sizes of 3 cm and 2 cm was performed
using the polynomial equation obtained from the trend-line.
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4.5

EPID PIXEL-TO-DOSE CALIBRATION

EPID images acquired were exported and displayed as a pixel value map for each
EPID detector element across the entire panel area. For dosimetry purposes the pixel
values in the EPID image were converted to dose using a Pixel to Dose Calibration
Factor (CFEPID:Dose(x,y)).

The calibration factor was calculated based on the average pixel value in the central
10 x 10 pixels (0.4 x 0.4 cm2) region for a reference field size irradiated onto the
panel, and the absorbed isocentric dose (in cGy) at the required reference depths for
each energy and panel as found in Section 4.3.
The reference field size used was 10.4 x 10.4 cm2 for the Elekta AxesseTM and 10 x
10 cm2 for the Siemens OncorTM.

CFEPID:Dose ( x, y ) 

Dosedref (cGy )
Pixel ( x, y )

(4.5.1)

EPID calibration factors were subsequently applied to all measured images for
conversion of pixel values to dose (cGy).

4.6

TREATMENT FIELD COMPARISONS

To use the EPID for dosimetry of conformal and IMRT fields, the response of all
pixels in the active detection area of the panel must be similar to those at an
equivalent depth in water (determined by field size factor measurements in Section
4.3).

EPIDs have been documented to have a sharper penumbra, a larger response in the
tail region due to scattering properties, and a flattened profile in the inter-umbral
region due to the Flood Field correction compared to planning systems and other
detectors (Greer 2005, Budgell et al. 2007, Gustaffson et al. 2009, Lee et al. 2009).
Scattering properties in the EPID due to panel construction and a high resolution
(0.4mm / pixel) contribute to the differences in dose profile between the EPIDs and
water. Dose profile comparisons were performed between the EPID panels and TPS54

generated dose profiles to examine the effect of the panel scatter properties on
dosimetry for the verification of treatment fields.

The XiO® v4.64 treatment planning system at the Prince of Wales Hospital was
modelled using measured beam data from the time of commissioning of each of the
LINACs. Measured data (profiles and PDDs) were collected using a small volume
(CC04) ionisation chamber in a 3-D scanning water tank. The IMRT beam models
for the Siemens and Elekta machines were used for calculations with a calculation
grid resolution of 0.2 cm set. The calculation method used was Superposition
(default method for all photon beam calculations in XiO®). The IMRT beam models
have been previously verified against measurements for model validation.

All treatment beams for comparison with EPID measured data were planned using
XiO® on a uniform density water phantom with dimension 40 x 40 x 40 cm3. The
beams planned with the TPS were exported at the reference depth determined for
each machine and energy.

4.6.1 Symmetric Open Field
EPID measured dose profiles for field sizes of 10 x 10 cm2 (Siemens) and 10.4 x
10.4 cm2 (Elekta) on the beam central axis in the A-B (cross-plane) direction for 6
and 10 MV X-ray beams were compared with profiles generated by XiO® at dref and
at dmax for each beam energy and LINAC.

EPID integrated images for a 100MU exposure were normalised to a value of 1 at the
central axis, with the cross-plane (central row [row index = 512]) and in-plane
(central column [column index = 512]) pixels extracted for analysis. Dose profiles
from XiO® were exported with the central cross-plane profiles extracted for
comparison with the EPID. The percentage dose difference (%DD) in the useful
beam (0.8 x Field size) was calculated between EPID and XiO® dose profiles. The
penumbral width (80% - 20%) and (90% - 10%) distances were also compared
between the EPID and TPS profiles.
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The penumbral widths for the EPID and XiO® profiles were calculated for each
energy and depth. The EPID penumbra was hypothesised to be smaller / steeper than
the penumbra calculated in water for the same radiation field due to the non-water
equivalence of construction materials in the EPID. The TPS used both a conformal
and an IMRT beam model for calculations. The conformal beam model was
measured with a small volume ion chamber and the IMRT beam model was
measured with a diode. Penumbral widths for ion chamber profiles were
hypothesised to be larger than those measured with the EPID due to volume
averaging effects.

The low-dose region (tail of the profile) for the EPID and XiO® profiles were
compared, with the maximum percentage difference between the profiles reported.

4.6.2 Asymmetric Open Field
The effect of an asymmetric field on the EPID output factor was measured using the
Siemens OncorTM accelerator and OptiVue 1000STTM EPID.

A rectangular field with the same equivalent square as a 10 x 10 cm field was
measured with the EPID and compared to ionisation chamber results for that same
field to ensure the output factor was equivalent for both dosimeters.
A 14 x 8 cm2 field was measured using the EPID with the output factor calculated
from normalisation of the central pixel region with that of the 10 x 10 cm2 field size.
Measurements were repeated with a NE2751 Farmer ionisation chamber on the
central axis in a solid water phantom. The ion chamber was positioned at the
reference depth for the EPID as measured in Section 4.3.

4.6.3 Picket Fence Field
Picket fence fields were created in XiO® v4.64 for the Elekta AxesseTM and the
Siemens OncorTM. The picket fence fields were planned as a static 20 x 20 cm2 field
with different MLC leaves extended across the field. Each of the treated fields
measured has a description of the MLC configuration displayed in Table 4.6.3.1. A
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diagram of the leaf configurations are displayed in Figure 4.6.3.1 with dark blue
areas representing regions of the treatment field underneath a projected MLC leaf,
and lighter blue areas representing regions of the treatment field that are exposed to
the beam and are between the MLC-shielded areas.
Table 4.6.3.1: Picket fence field names and description for TPS / EPID comparison.
Treatment field
name

Description

101

1 leaf extended, with 1 leaf gap between

102

1 leaf extended, with 2 leaf gap between

104

1 leaf extended, with 4 leaf gap between

201

2 leaf extended, with 1 leaf gap between

202

2 leaf extended, with 2 leaf gap between

204

2 leaf extended, with 4 leaf gap between

301

3 leaf extended, with 1 leaf gap between

302

2 leaf extended, with 2 leaf gap between

304

3 leaf extended, with 4 leaf gap between

Figure 4.6.3.1: Picket fence fields delivered to the Siemens OptiVue 1000STTM. (a)
101, (b) 102 and (c) 103.

Each treatment field was calculated using 6 MV and exported at the reference depth
of 7 cm for the Elekta and Siemens EPIDs. 6 MV was used for comparison as at this
energy as it provides a steeper penumbra than for 10 MV, hence differences in
agreement between profiles would be greater than at a higher beam energy where the
57

penumbra is wider. Gamma analysis was used for comparison of the treatment field
with gamma criteria set from 1 cGy / 1mm up to 3 cGy/3mm. These fields provide a
range of conditions to test the EPID dose response under varying scatter conditions.
For example depending on the MLC pattern the regions underneath the extended
MLC leaves are subject to differently weighted components of short and long range
EPID scatter originating from the exposed detector regions, and MLC transmission.
These experiments are designed to provide insight into the factors affecting
agreement between EPID and dose in water under varying conditions of intensity
modulations and to validate the choice of dref which was based on open field
response.

4.7

IMRT / VMAT DOSE VERIFICATION

Patient IMRT and VMAT treatment fields were measured prior to the first fraction of
treatment with the EPID and the MapCHECK® 2-D diode array and compared to
TPS-generated planar dose fluences. Individual IMRT and VMAT treatment fields
were measured with the EPID and MapCHECK® array for a variety of treatment
areas using 6 and 10 MV photon beams. Each IMRT / VMAT beam was measured in
QA mode with the gantry, collimator and couch angles set to zero degrees. VMAT
beams were collapsed to a gantry angle of 0° for measurement and TPS comparison
using the Elekta iViewGTTM EPID. Any dependence of the dose distribution on
gantry angle will not be seen when collapsing the VMAT arc in these measurements.
The dependence with gantry rotation may have a small effect on measured results,
however the movement (sag) in the EPID panel with gantry rotation would likely
mask these effects and create larger offsets in the measured images.

4.7.1 IMRT / VMAT TPS Fluence map generation
Dose fluences were generated for each IMRT patient field using XiO® v4.64 and
Monaco® v3.1 planning systems (Elekta AB, Stockholm, Sweden). XiO® uses a
Superposition algorithm for dose computation whereas Monaco® dose calculation is
based on a Monte Carlo algorithm.
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QA fields were created by transferring the patient plan to a virtual water phantom
with dimensions 40 x 40 x 40 cm on XiO®, and onto a CT scan of a solid water
phantom with dimensions of 30 x 30 x 30 cm for Monaco®. Due to software
restrictions, Monaco® could not calculate dose on a virtual phantom.

The planar dose maps were calculated using 100 cm source-to-detector distance
(SDD) at depths corresponding to dref for EPID QA beams and at a depth of 3.0 cm
for MapCHECK® QA beams. The planar dose maps for each IMRT beam was
exported at these depths for EPID and MapCHECK® plans respectively.

4.7.2 IMRT / VMAT Analysis
IMRT field-by-field comparisons were performed using gamma analysis with
clinical criteria of 3 cGy / 3 mm, and a 10% low dose threshold. A minimum of 95%
of points passing the criteria was a requirement for plan approval. The IMRT suite in
RIT v5.3 (Radiological Imaging Technology, Colorado Springs, USA) was used for
Elekta iViewGTTM gamma analysis. OmniPro I’mRT (IBA Dosimetry GmbH,
Schwarzenbruck, Germany) was used for Siemens OptiVue 1000STTM gamma
analysis. Different programs were used for IMRT / VMAT comparisons due to
compatibility issues with the different vendor image formats.

Gamma analysis results, including the measured and planned dose planes for a head
and neck field is shown in Figure 4.7.2.1. Regions of blue indicate areas in both
fields that are within the gamma criteria of 3 cGy / 3 mm. 3 cGy / 3 mm criteria was
used due to the limitation of the OmniPro software, where a percentage deviation is
not readily calculated between the measured and planned profiles, but a cGy
difference is reported and used for gamma analysis. Areas of red indicate areas
where the measured and planned dose maps do not satisfy the gamma analysis
criteria.
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Figure 4.7.2.1: IMRT field comparison between (a) an EPID measured IMRT
fluence, and (b) a TPS-generated fluence for the IMRT field. The gamma analysis
result for the field comparison is shown in (c).

The gamma analysis result includes the number of pixels in the dose-map
comparison that pass the 3 cGy / 3 mm criteria as a percentage of the total pixels in
the image.
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5 RESULTS

Results for the methods in Chapter 4 of this thesis are presented below.

5.1

REPRODUCIBILITY
The short term reproducibility of the Elekta iViewGTTM and the Siemens
OptiVue 1000STTM EPID panel were determined using repeat irradiations of
the panel in a single session and evaluating the percentage standard deviation
in average pixel value at the centre of the field. The percentage standard
deviations for each panel response to 10 repeat irradiations are displayed in
table 5.1.1.

Table 5.1.1: EPID short-term reproducibility (percentage standard deviation in pixel
value) for 10 repeat irradiations of the Elekta iViewGTTM and Siemens OptiVue
1000STTM.
Percentage standard deviation (%)

5.2

6 MV

10 MV

Elekta iViewGTTM

0.04

0.01

Siemens OptiVue 1000STTM

0.04

0.04

LINEARITY

Linearity for the Elekta iViewGTTM and the Siemens OptiVue1000STTM were
calculated independently of the LINAC for both 6 and 10 MV deliveries of 1 – 200
MU by use of an independent ion chamber beneath the treatment beam.
The Elekta iViewGTTM panel has user-defined settings for image acquisition. These
settings include the number of frames acquired by the panel following the end of
radiation (beam-off) called ‘PostBeamOffFrames’. This parameter was set as a
default by Elekta for optimisation for patient imaging. The EPID collects three
frames following radiation beam termination, increasing the number of frames
acquired for all deliveries. Deliveries between 1 – 3 MU were seen to be largely
influenced by this parameter, with a small signal collected by the EPID in a larger
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amount of frames. The EPID linearity deviated from unity with smaller MU
exposures due to the larger ratio of measurement frames to ‘PostBeamOffFrames’
with deviations up to± 7.8 % for 6 MV and ± 11.0 % for 10 MV. The
‘PostBeamOffFrames’ parameter was subsequently set to zero with linearity
exposures repeated. The linearity of the EPID improved with deviations of ± 4.1 %
for 6 MV and to ± 3.5 % for 10 MV.
Linearity measurements for the iViewGTTM for 6 and 10 MV using the
‘PostBeamOffFrames’ parameter set to 3 (imaging default) and 0 are displayed in
Figures 5.2.1 to 5.2.2.

Figure 5.2.1: 6 MV linearity for Elekta iViewGTTM EPID with ‘PostBeamOffFrames’
setting set to 3 and 0, independent of the linear accelerator monitor chamber for 1200 MU delivery.
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Figure 5.2.2: 10 MV linearity for Elekta iViewGTTM EPID with
‘PostBeamOffFrames’ setting set to 3 and 0, independent of the linear accelerator
monitor chamber for 1 - 200 MU delivery.

Due to small MU deliveries for individual segments in an IMRT field, it was decided
that the ‘PostBeamOffFrames’ parameter would be set to zero for all dosimetry
image acquisitions with the EPID.
The Siemens OptiVue 1000STTM has pre-set image acquisition settings that cannot
be modified by the user (i.e. number of frames acquired following termination of
radiation). These settings are optimised for patient imaging and required testing to
assess the EPID response to delivered dose.
Linearity measurements for the Siemens OptiVue1000STTM EPID for 6 and 10 MV
photon beams are presented in Figures 5.2.3 to 5.2.4.
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Figure 5.2.3: 6 MV linearity for the Siemens Optivue1000STTM EPID independent of
the linear accelerator monitor chamber for 1 - 200 MU delivery.

Figure 5.2.4: 10 MV linearity for the Siemens Optivue1000STTM EPID independent
of the linear accelerator monitor chamber for 1 - 200 MU delivery.
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All linearity plots have large error-bars for the low-MU deliveries. This is due to the
instability of measurement of low MU irradiations and can also be attributed to
incomplete charge collection from the panel due to frame acquisition.

Figure 5.2.4 displays a dip in detector linearity around 2 and 3 MU. This was
attributed to image lag and ghosting effects with small MU deliveries affecting the
signal from the panel from a small MU delivery.
The OptiVue 1000STTM was found to have a maximum deviation from unity of± 4.5
% for 6MV and ± 4.6 % for 10 MV in the range of 1 – 200 MU.

5.3

FIELD SIZE DEPENDENCE

EPID and ionisation chamber response as a function of field size for the Elekta
iViewGTTM and the Siemens OptiVue1000STTM are presented in Figures 5.3.1 to
5.3.8. Qualitatively, the closest fit can be found between the EPID panel and a
specific depth in water. Quantitative comparison between EPID and different depths
in water was performed by computing the sum of square difference for each depth in
water and the EPID. The lowest resulting sum square of difference between curves
indicated the closest agreement between EPID field size response and ionisation
chamber response, and indicated a reference depth in water (dref) that the EPID
output matched.
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Figure 5.3.1: iViewGTTM output factor comparison to ionisation chamber output
factors for different depths in water for a 6 MV beam.

Figure 5.3.2: EPID, planning system and ionisation chamber comparison for d=7
cm using the Elekta iViewGTTM EPID.
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Elekta iViewGTTM 6MV field size responses are presented in Figures 5.3.1 and 5.3.2.
A depth of 7 cm in water was determined as the dref for 6MV with a sum square of
differences value of 0.001.

Figure 5.3.3: iViewGTTM output factor comparison to ionisation chamber output
factors for different depths in water for a 10 MV beam.

Figure 5.3.4: EPID, planning system and ionisation chamber comparison for d=10
cm using the Elekta iViewGTTM EPID.
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A depth of 10 cm in water was determined as the dref for 10 MV with a sum square of
differences value of 0.0002 calculated between measurements.
Field size response comparison between the Siemens OptiVue1000STTM EPID and
ionisation chamber measurements are presented in Figures 5.3.5 to 5.3.8.

Figure 5.3.5: Optivue 1000STTM output factor comparison to ionisation chamber
output factors for different depths in water for a 6 MV beam.
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Figure 5.3.6: 6 MV EPID, planning system and ionisation chamber comparison for
d=7cm using the Siemens Optivue 1000STTM EPID.

A depth of 7 cm was calculated as the reference depth in water (dref) for the
OptiVue1000STTM for 6 MV irradiations. The sum square of differences was
calculated as 0.0006 between the EPID and the CC04 at 7 cm depth. 10 MV EPID
and ionisation chamber comparisons are presented below for the OptiVue1000STTM,
with a reference depth of 12 cm found for the EPID for 10 MV irradiations.
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Figure 5.3.7: Optivue 1000STTM output factor comparison to ionisation chamber
output factors for different depths in water for a 10 MV beam.

Figure
5.3.8: 10 MV EPID and ionisation chamber comparison for d=12 cm using the
Siemens Optivue 1000STTM EPID.

The sum square of differences was calculated for the EPID and CC04 ionisation
chamber at all depths, with the lowest value found at a depth of 12 cm, 0.0017.
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The dref was found for each EPID at 6 and 10MV beam energies, and is presented in
Table 5.2.1. The reference depths presented were subsequently used for open field
and IMRT dosimetry comparisons, presented in Section 5.6 and 5.7.

Table 5.3.1: Summary of reference depths in water for different vendor EPIDs for 6
and 10MV photon beams.
Siemens OptiVue

Elekta iViewGTTM

1000STTM

Photon Beam Energy

Equivalent depth in

Equivalent depth in

(MV)

water (cm)

water (cm)

6

7

7

10

10

12

5.4

EPID SCATTER FACTOR MEASUREMENTS (Spe)

The Spe was calculated for each field size and energy using Equation 4.4.2. Results
for the Elekta iViewGTTM and the Siemens OptiVue 1000STTM for 6 and 10 MV
with comparison to the reference depth in water for the chosen beam energy are
presented in Figure 5.4.1 to 5.4.4.
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Figure
5.4.1: 6 MV comparison of Elekta iViewGTTM panel scatter as a function of field size
with the phantom scatter in water at a depth of 7 cm and at depth of maximum
absorbed dose.

Figure
5.4.2: 10 MV comparison of Elekta iViewGTTM panel scatter as a function of field
size with the phantom scatter in water at a depth of 10 cm and at depth of maximum
absorbed dose.
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Figure 5.4.3: 6 MV comparison of Siemens Optivue 1000STTM panel scatter as a
function of field size with the phantom scatter in water at a depth of 7 cm and at
depth of maximum absorbed dose.

Figure 5.4.4: 10 MV comparison of Siemens Optivue 1000STTM panel scatter as a
function of field size with the phantom scatter in water at a depth of 12 cm.
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Differences between the measured Spe for each panel and the Sp for the reference
depth in water for each energy were calculated. A maximum local percentage
difference of 1.85% and 0.75% was calculated for the Elekta EPID, -0.85% and 0.50% was calculated for the Siemens EPID for beam energies of 6 MV and 10 MV
respectively. The marker for the Elekta iViewGTTM was reduced in size in Figures
5.4.1 – 5.4.2 to enable visualisation of the error bars. The error bars in all EPID
scatter measurement plots are attributed to the stability and reproducibility of each of
the panels with irradiations of 100 MU.

5.4.1 Collimator Scatter, Sc measurements
The charge collected using the NE2571 ion chamber in the Perspex mini-phantom
was normalised for each field size to the collected charge obtained for the 10.4 x 10.4
cm2 and 10 x 10 cm2 field sizes for the Elekta AxesseTM and Siemens OncorTM
LINACs respectively. The normalised data was plotted as a function of field size,
with a polynomial trend-line fitted. Extrapolation of the data to the smaller field sizes
of 3 cm and 2 cm was performed using the polynomial equation obtained from the
trend-line.
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Figure 5.4.1: Collimator scatter factor for Elekta Axesse as a function of field size
foe 6 and 10 MV beam energies. The lines represent a 3rd order polynomial trend
line fitted to the data.

Figure 5.4.2: Collimator scatter factor for Siemens Oncor as a function of field size
foe 6 and 10 MV beam energies. The lines represent a 3rd order polynomial trend
line fitted to the data.
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Trend lines were extracted from the polynomial fit and were used to calculate the Sc
for the smallest field sizes. The trend line equations are provided in table 5.4.1.

Table 5.4.1: Trend line equations for 3rd order polynomial fit of collimator scatter
data for the Elekta and Siemens linear accelerators.
Equation of 3rd order polynomial from Sc
measurements
Elekta Axesse

Siemens Oncor

5.5

6 MV

y = 0.920 + 0.146x - 0.001x2 + 0.00005x3

10 MV

y = 0.928 + 0.117x - 0.001x2 + 0.00001x3

6 MV

y = 0.887 + 0.018x - 0.001x2 + 0.00001x3

10 MV

y = 0.901 + 0.016x - 0.001x2 + 0.00001x3

EPID PIXEL-TO-DOSE CALIBRATION

Calibration for the EPID panels was performed for 6 and 10 MV energies.
Calibration factors were computed at each time of measurement using the central 10
x 10 pixel values at the centre of the EPID field and the dose (in cGy) on the beam
CAX at dref for each EPID and beam energy. The calibration factor was subsequently
applied to all measured fields with the EPID.

5.6

RADIATION FIELD COMPARISONS

5.6.1 Symmetric Open Field
Open fields were compared across the central axis of the measured and planned
profiles. The profile from the central row of detectors was extracted from the EPID
panels and compared against the central axis dose profile of the planned field. The
dose profiles for Elekta and Siemens EPID images for 6 and 10 MV, compared with
profiles generated at dmax and dref using the TPS are presented in figure 5.6.1.1.
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Figure 5.6.1.1: Dose profile comparisons between EPID and TPS-generated dose
profiles at dmax and dref for (a) Elekta 6 MV, (b) Elekta 10 MV, (c) Siemens 6 MV and
(d) Siemens 10 MV nominal beam energies.

The percentage dose difference (%DD) was calculated between the EPID and TPS
dose profile. The TPS dose profile was calculated at a depth of dmax and at the
reference depth, dref for each energy. The %DD was calculated for the fields in the
useful beam only which was the central 80% of the profile. This equated to a field
size of 8.3 cm for Elekta profiles and 8.0 cm for the Siemens profiles.
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Figure 5.6.1.2: 6 MV (a) and 10 MV (b) profile comparison and corresponding
percentage dose difference plots (c) and (d) (b) for the Elekta iVireGTTM and XiO
planned profiles.
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Figure 5.6.1.3: 6 MV (a) and 10 MV (b) profile comparison and corresponding
percentage dose difference plots (c) and (d) (b) for the Siemens OptiVue 1000STTM
and XiO planned profiles.

Due to the flattening effect of the FF calibration, the characteristic horns on the dose
profiles were removed when measured with the EPID. As a result the dose profiles
were found to more closely match profiles at greater depths in water where the beam
profile is flatter. Comparison of the useful beam dose between the EPID and water
provided agreement across the field to within 4.5% for 6 MV profiles at the reference
depth of 7 cm and agreement to within 2.1% across the profile for 10 MV at the
different reference depths for both Elekta and Siemens LINACs. A difference in
profile agreement between the EPID and water was observed between the 6 MV and
10 MV energies, with the 10 MV EPID profiles having closer agreement with the
profiles in water. This difference was attributed to the higher mean energy of the
radiation beam causing increased lateral scattering range of the electrons in the panel
which more closely matched the scatter in water.
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The distance between the 80% - 20% and 90% - 10% points on the dose profile were
used to calculate the penumbral width of the EPID and dose in water. The dose in
water was calculated at a depth of maximum absorbed dose and at the reference
depth for each energy. Penumbral regions for Elekta and Siemens EPID and TPS
dose profiles are shown in figure 5.6.1.4 for 6 and 10 MV energies.

Figure 5.6.1.4: Penumbral regions for EPID and TPS-generated dose profiles for (a)
Elekta 6MV, (b) Elekta 10MV, (c) Siemens 6MV, and (d) Siemens 10MV dose
profiles.
The penumbral width (in mm) was calculated using the distance between the 80%
and 20% points on the dose profile with calculated penumbral widths presented in
Table 5.6.1.1 for the Elekta iViewGTTM and in Table 5.6.1.2 for the Siemens
OptiVue 1000STTM.
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Table 5.6.1.1: 80% – 20% and 90% - 10% penumbral width comparison for 6MV
and 10 MV Elekta iViewGTTM profiles compared to profiles generated in a water
phantom on XiO®.
80% - 20%

90% - 10%

Penumbral width

Penumbral width

(mm)

(mm)

3.0

7.8

XiO d=1.5 cm

6.0

9.5

XiO d=7 cm

6.9

13.1

2.6

5.3

XiO d=2.2 cm

6.6

10.4

XiO d=10 cm

7.7

14.2

Machine
Energy
EPID

EPID

6 MV

10 MV

Table 5.6.1.2: 80% – 20% and 90% - 10% penumbral width comparison for 6MV
and 10 MV Siemens OptiVue 1000STTM profiles compared to profiles generated in a
water phantom on XiO®.
80% - 20%

90% - 10%

Penumbral width

Penumbral width

(mm)

(mm)

4.2

8.0

XiO d=1.5 cm

4.2

8.2

XiO d=7 cm

6.0

11.1

2.6

6.0

XiO d=2.2 cm

3.3

7.0

XiO d=12 cm

8.0

11.0

Machine
Energy
EPID

EPID

6 MV

10 MV

Penumbral widths measured by the EPID were sharper than those generated by the
TPS at depths of dmax and at dref for both 6 and 10 MV energies. This difference is
attributed to the shorter distances of electron lateral scatter in the EPID panel (due to
construction materials) compared to the distance of electron lateral scatter in water.
Differences in the penumbral widths measured with each EPID are related to
differences in construction of the panel, hence different scattering properties will
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characterise the panel response and contribute to the penumbral shape. Differences in
TPS penumbral width depend on the individual LINAC and jaw / MLC design, as a
result the widths (as modelled in the TPS) will be difference for the Elekta and
Siemens LINACs. The effect of the penumbral width on modulated and IMRT
measurements was monitored in Section 5.6.3 and 5.7. The low dose region of the
dose profiles were compared between the EPID and XiO® for 6 and 10 MV
energies, with the EPID profiles matching those at dref to within ± 4% in the region
below 10%.

Figure 5.6.1.5: Percentage difference calculated between the EPID and planning
system profiles in the tail region for (a) Elekta – 6 MV, (b) Elekta – 10 MV, (c)
Siemens - 6 MV, and (d) Siemens – 10 MV beams.

5.6.2 Asymmetric Open Field
The measured output factors for the 14 x 8 cm2 rectangular field were compared
between ion chamber and the EPID. An output factor was calculated for the EPID as
0.999 and for the ion chamber as 0.994. This equated to a difference of 0.5%
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between the detectors. The difference in field shape was determined not to have a
significant effect on the EPID sensitivity / dose response.
5.6.3 Picket Fence Field
Picket fence fields listed in Table 4.5.3.1 were planned using XiO® v4.64 and
measured with EPID panels on the Elekta AxesseTM and Siemens OncorTM LINACs
with a 6 MV beam.
Gamma analysis was performed between measured and planned dose distributions
for all modulated fields using 3 cGy / 3mm criteria with a 10 % low dose threshold.

Figure 5.6.3.1: Comparison of 6 MV picket fence fields between EPID dose profiles
measured with the Siemens OptiVue 1000ST (red) and XiO® calculated dose profiles
at dref (7 cm) (green). Note that the number of leaves between the open regions of the
field increases from (a) one to (c) three.
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With one leaf projected into the treatment field (as shown in (a) of Figure 5.6.3.1) the
TPS calculated dose profile could not accurately model the modulated field. This was
due to the contribution of the low-dose penumbra and tail from either side of the
MLC leaf. With the field decreasing in modulation from the worst-case scenario (as
seen in (b) and (c)), the dose profiles more closely match and provide better
agreement with gamma analysis comparison.

Gamma analysis was performed for all measured and planned field combinations
using gamma criteria from 1 cGy / 1 mm up to 3 cGy / 3mm. Results for the
iViewGTTM and OptiVue1000STTM are presented in Table5.6.3.1 and Table 5.6.3.2
respectively.
Table 5.6.3.1: 6 MV Elekta iViewGTTM gamma analysis results for Picket Fence
fields planned with XiO® at a depth of 7 cm.
1%

1%

1%

2%

2%

2%

3%

3%

3%

1mm

2mm

3mm

1mm

2mm

3mm

1mm

2mm

3mm

101

16.3

25.8

29.4

19.3

28.2

31.8

21.8

30.6

34.1

102

30.2

24.3

30.2

18.5

27.6

33.8

21.4

31.0

37.5

104

34.3

52.2

63.5

44.8

58.7

67.3

50.7

63.6

71.5

201

19.2

39.4

45.7

22.9

39.4

50.2

26.2

42.1

53.2

202

18.8

32.9

41.6

24.0

39.6

48.2

26.3

41.9

50.7

204

35.6

56.7

68.0

47.4

66.3

76.6

55.7

72.3

80.4

301

21.1

39.9

52.7

25.4

49.0

58.9

28.7

51.6

60.8

302

19.0

35.4

47.6

24.9

44.1

56.0

27.1

46.3

58.3

304

39.4

58.8

77.1

52.9

77.1

91.8

60.3

83.5

94.3

Field
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Table 5.6.3.2: 6 MV Siemens OptiVue 1000STTM gamma analysis results for Picket
Fence fields planned with XiO® at a depth of 7 cm.
1%

1%

1%

2%

2%

2%

3%

3%

3%

1mm

2mm

3mm

1mm

2mm

3mm

1mm

2mm

3mm

101

26.3

44.0

51.1

39.0

59.5

66.9

49.7

71.0

77.1

102

45.8

57.6

62.4

57.6

72.6

76.3

66.0

82.0

85.3

104

57.0

68.4

74.5

70.4

84.3

84.3

77.0

88.0

90.2

201

28.4

52.5

63.4

47.9

77.2

87.1

59.4

92.1

97.3

202

28.4

52.5

63.4

47.9

77.1

87.5

65.3

93.1

98.8

204

56.9

74.0

80.2

72.4

89.5

91.9

82.8

98.0

98.9

301

28.4

50.1

61.1

51.6

79.5

88.6

61.9

94.6

97.5

302

44.2

63.7

70.8

61.7

84.4

88.6

72.1

95.3

97.5

304

62.5

77.6

81.8

75.1

90.1

92.2

82.8

97.1

98.2

Field

As the degree of modulation decreases from the highest modulation, with one leaf
projected into the field between small open field regions, to an increase in distance
between the projected leaves, the percentage of pixels passing the set gamma criteria
also changes. The lowest pass rates for the Elekta iViewGTTM and the Siemens
OptiVue 1000STTM were obtained for the field with alternating leaves projected into
the treatment field with 1 leaf open between the leaves (16.3 % and 26.3 %
respectively). The highest pass rates were obtained for the fields with a larger gap
between the closed leaves.

Differences were observed between the Elekta and the Siemens pass rates for the
picket fence field. The Elekta panel had significantly lower pass rates for the fields
with the highest degree of modulation. This was attributed to the differences in
penumbra width for the EPID and the TPS (as reported in section 5.6.1). Differences
between the pass rates for the picket fence between panels would not be clinically
significant as IMRT and VMAT fields generally do not have this degree of
modulation and clinical gamma analysis criteria of 3 %, 3 mm is used.
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5.7

IMRT / VMAT DOSE VERIFICATION

Gamma analysis was performed on patient IMRT and VMAT fields measured with
the EPID and the current department standard dose verification QA tool, the
MapCHECK® diode array. Gamma criteria of 3 cGy / 3 mm, with a 10 % low dose
threshold was used for all comparisons between measured and planned dose
fluences. A 95 % pass rate (clinical acceptance rate) was used for each IMRT beam
measured.

The percentage of points passing the gamma criteria was calculated between the TPS
(XiO® or Monaco®) and measurements obtained with the EPID and MapCHECK®.
The average gamma result for the entire patient treatment (i.e. average pass rate for
all IMRT beams measured for a patient) was calculated for both measurement
techniques and compared.

Individual treatment fields that differed by > 3 % in gamma pass rate between the
two measurement techniques were subject to further investigation. Individual beams
with gamma pass rates less than 95% were also investigated for their cause.
Eight patients were compared for the Elekta AxesseTM LINAC. Of these eight, five
were step-and-shoot IMRT and three were collapsed gantry VMAT deliveries. The
iViewGTTM gamma results are displayed along-side the MapCHECK® results for
each patient. Four patients were treated with 6 MV photons, and four were treated
with 10 MV.
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Table 5.7.1: Elekta iViewGTTM EPID and MapCHECK® diode array average plan
gamma analysis result for step-and-shoot IMRT treatments on the Elekta AxesseTM
linear accelerator.
Percentage pixels passing gamma analysis per plan (%)
Patient

Treatment Site

1

Prostate

2

Energy

EPID

MapCHECK

6

97.8

99.0

Sacrum

6

95.6

98.2

3

Paranasal Sinus

6

94.5

96.1

4

Lung

10

96.5

99.9

5

Prostate

10

97.7

99.1

(MV)

Table 5.7.2: Elekta iViewGTTM and MapCHECK® diode array average plan gamma
analysis result for VMAT collapsed gantry QA fields on the Elekta AxesseTM linear
accelerator.
Percentage pixels passing gamma analysis per plan (%)
Patient

Treatment Site

6

Nasopharynx

7
8

Energy

EPID

MapCHECK

6

97.2

99.6

Head and neck

10

97.4

100.0

Pancreas

10

98.0

99.7

(MV)

Gamma analysis results for IMRT pre-treatment QA were comparable to the results
obtained when the fields were measured using the MapCHECK® diode array. A
maximum difference of ± 2.6 % was found between the iViewGTTM and
MapCHECK® for all step-and-shoot and VMAT fields. An average difference of
±2.1 % was calculated for all treatments. All patient IMRT plans measured had a
plan-average gamma analysis pass-rate greater than 95%.

Three out of 35 EPID and one out of 35 MapCHECK® individual measured beams
had pass rates <95%. One of these beams did not pass either measurement method
and was further investigated for MLC leaf positioning or planning errors. The
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position of the MLC leaves was verified with MLC QA and an investigation of the
patient plan found no significant errors in the TPS or in the transfer of the plan to the
record and verify system (LINAC delivery system). With no significant errors found
and with the pass rate above90% for both measurement methods (EPID and
MapCHECK), the beam was deemed to be acceptable for patient treatment. It must
be noted that department protocol specified a minimum 90% pass rate, hence the
beam passed clinical pass rates for plan acceptance.
Ten patients were compared for the Siemens OncorTM LINAC. The OptiVue
1000STTM gamma results are displayed along-side the MapCHECK® results for
each patient. Seven patients were treated using 6 MV photons, and three patients
were treated with 10 MV photons.
Table 5.7.3: Siemens OptiVue 1000STTM and MapCHECK® diode array average
plan gamma analysis result for IMRT treatments on the Siemens OncorTM linear
accelerator.
Percentage pixels passing gamma analysis per plan (%)
Patient

Treatment Site

9

Hypo-pharynx

10

Energy

EPID

MapCHECK

6

99.3

98.4

Head & Neck

6

98.5

100.0

11

Base of Tongue

6

98.6

99.3

12

Head & Neck

6

99.4

98.5

13

Tonsil

6

99.4

99.2

14

Nasopharynx

6

97.5

99.1

15

SCC

6

97.4

98.8

16

Prostate Bed

10

96.5

97.2

17

Anus

10

97.6

99.5

18

Anus

10

96.6

96.9

(MV)

Gamma analysis results for IMRT pre-treatment dose verification QA were
comparable to the results obtained when the fields were measured using the
MapCHECK® diode array. A maximum difference of ± 1.9 % was found between
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the Optivue 1000STTM and MapCHECK® for all IMRT fields. An average
difference of ±0.6 % was calculated for all treatments. All patient IMRT plans
measured had a plan-average gamma analysis pass-rate greater than 95%.

2 out of 57 EPID and 3 out of 57 MapCHECK® individual measured beams had pass
rates <95%. One of these beams did not pass either measurement method and was
further investigated for MLC positioning and plan calculation errors, again careful
analysis of the MLC and the patient plan on the TPS was performed with no
significant errors found.
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6 ANALYSIS OF ERRORS

Uncertainties presented in this thesis are Type A uncertainties which are errors resulting
from random fluctuations in measurement both in a measurement session and between
measurement sessions. In this thesis Type A uncertainties include detector
reproducibility, pixel age and function, variations in detector setup, panel positioning,
and beam output. Type A uncertainties presented in the graphs in this thesis are based
on 1SD of the measurements acquired for each setup.

Type B uncertainties include systematic uncertainties present in the study that are
related to the measurement setup. Type B uncertainties that must be considered when
reviewing this thesis include variations in EPID panels of the same type due to
manufacturing differences between the EPIDs used in this study and those outside of
this study set (of the same detector-type). Type B uncertainties can be derived from
previous experience and from published data (Bell 1999).

An overall estimate of detector uncertainty can be obtained by adding Type A and Type
B uncertainties in quadrature for all measurements, providing a total uncertainty which
is approximately twice that of the Type A uncertainties.

Methods to reduce uncertainties in this thesis were to ensure EPID panels were
regularly serviced, with panel alignment, positioning and imaging QA performed on a
quarterly and daily basis respectively. Variations in beam output due to daily
fluctuations were minimised by measuring the absorbed dose at the reference depth and
acquiring a calibration field with the EPID prior to all measurements. The absorbed
dose and the reference image were used to calibrate all subsequent patient QA images to
absolute dose. IMRT fields measured with the EPID and MapCHECK® in the same
session to eliminate output fluctuations in the radiation beam.
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7 DISCUSSION

This thesis addresses the need for efficiency and accuracy in IMRT / VMAT dose
verification QA in a limited-resource radiotherapy department by developing and
evaluating a vendor-independent dose verification QA system using EPIDs. This work
was based on a model for IMRT verification using Varian EPIDs presented by Lee et al.
(2009). The method presented by Lee et al. (2009) was modified and extended upon to
include equipment from different vendors, different treatment planning systems, and to
include verification of VMAT. The development of the QA system included a
comprehensive investigation of EPID dosimetric properties, determination of an
equivalent depth in water where the EPID properties match that of water, EPID pixel-todose calibration, and comparison of EPID measured vs. TPS calculated dose planes for
conformal and IMRT / VMAT fields.

EPID dosimetric properties examined in this thesis included short-term reproducibility,
linearity, field size response, and EPID scatter. The short term reproducibility of both
Elekta and Siemens EPIDs was found to be within 0.4%, which was consistent with
0.5% found by Deshpande et al. (2011). EPID linearity has been reported for Elekta
EPIDs by Budgell (2005), Winkler et al. (2006), and for Siemens EPIDs by Deshpande
et al. (2011) with results indicating a loss of linearity of the panel response with low
MU deliveries of up to 7% (Budgell et al. 2005). EPID linearity reported in chapter 5 of
this thesis support results published by the above-mentioned authors, with panel
linearity decreasing by up to 8% for low MU deliveries. Differences in panel
construction, electronics, and read-out systems could contribute to different linearity
values and as a result, EPID linearity must be measured and documented prior to
implementation of a QA program. The field size response and subsequent generation of
an EPID scatter factor was investigated by comparing the response of the EPID to field
sizes from 2 x 2 cm2 up to 22 x 22 cm2, to the response of an ion chamber in water at
different depths. EPID field size response and scatter factor has been measured by Greer
and Popescu (2003), Winkler et al. (2006), Nijsten et al. (2007), Van Esch et al. (2007)
and Deshpande et al. (2011) with a maximum difference of 9% found between ion
chamber measurements at depth of maximum absorbed dose and the EPID. Gustaffson
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et al. (2009) published that the non-water equivalence of the panel was due to the higher
densities of the panel construction materials causing a change in response with energy
spectrum. Consistent with Gustaffson et al. (2009), this thesis measured different
phantom scatter properties between EPIDs and water at dmax. The steeper slope of the
EPID response to a changing field size compared to dmax was attributed to differences in
construction materials and the scatter properties of the panel. This indicated that the
EPID approximates a water-equivalent detector at given reference depths. EPID scatter
factors were compared with the phantom scatter in water at dref for both the Elekta
iViewGT and the Siemens OptiVue 1000ST panels, with a maximum local percentage
deviation of 1.85% calculated between EPID and water at the reference depth.

A depth in water where the EPID scatter properties match that of water was investigated
by Lee et al. (2009) for Varian EPIDs, with a depth of 5 cm in water found to be
equivalent to the EPID response in a 6 MV beam. The Elekta and Siemens EPIDs were
characterised in this thesis to have equivalent (reference) depths (dref) of 7 cm for 6MV
photons for both panels. A depth of 10 cm for the Elekta and 12 cm for the Siemens
EPID was determined as the EPID water equivalent depth for 10 MV photons.
Absorbed dose at the reference depth in water in a 10 x 10 cm field size was then used
to calibrate EPID pixel value to dose for extraction and analysis of absorbed dose
fluence maps from the EPID.

Comparison of EPID ‘dose’ images with TPS-generated fluence maps at dref for each
panel was performed with conformal and IMRT fields. Conformal field comparison of
open beams between the EPID and water provided agreement across the useful field
(central 80% of the field) to within 4.5% for 6 MV profiles at the reference depth of 7
cm and agreement to within 2.1% across the profile for 10 MV at the different reference
depths. Penumbral widths for fields measured with the EPIDs were sharper than those
generated by the TPS at both a depth of dmax, and at dref, with an average of 4.0 mm and
2.0 mm for the Elekta and Siemens EPIDs respectively. The difference in penumbral
width obtained between the EPID panels and the dose in water is due to scatter in the
panel being different to that of water (due to the construction materials of the panel
being non-water equivalent), and also due to the high resolution of the EPID (0.4 mm /
pixel) compared to the resolution of the dose profiles generated with the TPS (1.0 mm).
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Differences in penumbral width were also observed between the different EPID models
which was attributed to the different construction and hence scattering properties of the
panels. It was hypothesized that these discrepancies in penumbral width could have an
effect on IMRT dosimetry measurements with the EPID, with test patterns of a highlymodulated picket fence field performed to test this. Gamma analysis comparison of
EPID-measured and TPS-planned picket fence fields were performed with higher pass
rates obtained for comparison with the Siemens OptiVue 1000STTM than with the
Elekta iViewGTM. This was attributed to the larger leaf width at the isocentre (5 mm)
for the Siemens compared to 4 mm for the Elekta, and differences in penumbral widths
in the TPS due to different MLC construction and shape (depending on the LINAC
make / MLC model). Pass rates for the highly-modulated fields demonstrated that the
effect of penumbral width plays a role in the pass rates calculated for EPID / TPS
comparisons, however the extent of modulation was extreme in these cases and
demonstrates a ‘worst-case’ scenario. A more clinically relevant degree of modulation
such as the 204 and 304 fields provided closer agreement between EPID and TPS and as
a result the EPID was used for measurement of IMRT and VMAT fields, comparing to
TPS-generated fluences.

IMRT and VMAT fields were measured with the EPID and MapCHECK® ion chamber
array and compared to TPS-generated fluence maps. The Patient IMRT QA pass rates
measured using the EPID for both Siemens and Elekta machines were comparable to the
current department standard of IMRT dose verification QA using the MapCHECK® 2D diode array. As a result of the IMRT / VMAT detector comparison, the EPID was
deemed to be a suitable tool for IMRT dose verification QA with the FF correction
intact.

This masters research thesis develops and provides a general model for per-patient pretreatment IMRT and VMAT dose verification QA using standard EPIDs that are
attached to modern linear accelerators.
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In particular, the thesis presents:
i.

Characterisation of flood field corrected images for Elekta iViewGTTM and
Siemens OptiVue 1000STTM EPID panels including panel reproducibility,
linearity with dose, and EPID response with variation field size, to determine
suitability of each EPID panel for dosimetry.

ii.

Determination of a reference depth in water (dref) for the Elekta iViewGTTM and
the Siemens OptiVue 1000STTM, for 6 and 10 MV nominal beam energies. The
reference depth is a depth in water where the scattering response of each EPID
detector panel closely corresponds to the scatter properties of a reference
dosimeter in water. The reference depth for each panel and energy were
subsequently used for calibration of to generate dose profiles in a TPS for
comparison EPID-measured and TPS-generated profiles for open and modulated
fields.

iii.

A method to calibrate flood-field corrected EPID images from pixel values to
dose, using the dose distribution in water at the reference depth for each panel
and energy. The resultant calibrated images were compared to TPS-generated
dose fluences at dref for both open and highly-modulated (picket fence) fields in
the inter-umbral, penumbral and low-dose regions. Dose profile comparisons
provided close agreement between the EPID panels and dref in these fields.

v.

Evaluation of the EPID dosimetry technique as a method for patient-specific
dose verification QA of IMRT and VMAT plans using any combination of
EPID, TPS, beam energy and delivery technique. The technique was tested on
numerous clinical IMRT and VMAT patients and compared to current
departmental QA methods using a commercial system. The method has been
developed and used as a clinical IMRT / VMAT QA tool, and is routinely used
as part of IMRT pre-treatment QA.

The ability to use equipment that is already present in the radiotherapy department
significantly reduces the financial burden of IMRT and VMAT implementation due to
the need for an accurate dosimeter. The EPIDs are attached to the LINAC and as a
result, the time taken for IMRT / VMAT dose verification QA measurements is
minimised as there is no set-up of external QA devices in the treatment room and at the
console, which can take up to an hour using 2D arrays. This minimises the constraint of
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time on the treatment machine for physicists and may allow the IMRT fields to be
delivered by the therapists in a ‘Fraction 0’ slot before the patient begins treatment.

The results obtained for both the Siemens and Elekta LINACs for the gamma analysis
of IMRT and VMAT fields using the EPID panels were comparable to the results
obtained by Lee et al. (2009) using Varian LINACs and EPID panels. As there is
currently no standard IMRT / VMAT dose verification QA technique across
radiotherapy departments due to the different equipment and techniques used for
verification of IMRT / VMAT, the model presented here could be used as a benchmark
to compare IMRT delivery across multiple centres using multiple vendor planning
systems and LINACs.
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8 CONCLUSIONS AND FUTURE WORK
The Elekta iViewGTTM and Siemens OptiVue 1000STTM EPID panels were investigated
for their suitability for IMRT and VMAT QA using clinical flood-field corrected
images. A simple vendor-independent EPID dosimetry procedure for use in pretreatment IMRT and VMAT dose verification QA was developed, evaluated and
implemented.

The EPID panels were deemed to be suitable for use as a radiotherapy dosimeter from
reproducibility and linearity measurements performed for 6 and 10 MV beams.
The panel energy response was characterised and evaluated with respect to water. A
reference depth in water was found at which the EPID panel scattering properties
matched that of water. The reference depth was found for each EPID panel for both 6
and 10 MV and validated by measurement of the Spe.

Following EPID pixel to dose calibration, the profile agreement between the EPID and
planning system was examined for open symmetric and asymmetric fields as well as
highly modulated fields. Results from comparisons indicated that while the EPID did
not provide good agreement with dose in water in the penumbral regions nor in some
highly modulated test patterns, the EPID demonstrated potential as a suitable dosimeter
for clinical radiotherapy fields, and the suitability for use in IMRT and VMAT fields
was subsequently investigated.

Poor agreement in penumbral width between the EPID and the planning system for
open fields has minimal effect in IMRT and VMAT treatments where individual
treatment segments are delivered to produce a modulated field. In IMRT treatment field
QA, the gamma analysis method is used whereby criteria of dose and distance to
agreement (explained in section 2.4). The differences in penumbral width across the
clinical fields were accounted for in the clinical DTA agreement criteria of 3mm, and
therefore penumbral width differences between EPID and the TPS do not affect the
gamma results for clinical IMRT fields. The highly-modulated picket fence test patterns
(with one leaf extended across the field) are not representative of clinical IMRT and
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VMAT treatment fields. The picket fence field was examined to analyse EPID response
in the worst case scenario and determine any limitations of the model. The main
observation found using the picket fence field was the limitation of the TPS to
accurately model the small gaps between adjacent leaves as the modelled penumbra of
each side of the field contributed to an increased dose in the shielded areas that was not
present in the EPID measurement.

Evaluation of IMRT and VMAT plan verification using the EPID was performed for
clinical IMRT and VMAT patient plans, with gamma analysis performed between the
EPID-measured and TPS-generated fluences. A variety of delivery techniques (sMLC
and dMLC), energies (6 and 10 MV), planning systems (XiO® and Monaco®), and
EPIDs (Elekta and Siemens) were used to validate the EPID QA procedure / system.
Gamma analysis results were compared with gamma analysis results for fluences
measured with the MapCHECK® diode array, which is the standard IMRT QA
measurement device at the Prince of Wales Hospital.

Using a gamma criteria of 3 cGy / 3mm for IMRT field comparison, all patient plans
had an average gamma pass rate above 95%. EPID results agreed with the
MapCHECK® diode array with an average difference of 1.3 % in gamma pass rates.

Results from this study indicate that the EPID IMRT / VMAT dose verification QA
procedure can be used as an accurate and reliable tool for per-patient pre-treatment dose
verification QA across different platforms and delivery techniques. Further assessment
is required to determine the procedures efficiency compared to the current standard
methods, and to implement the system across multiple-departments with a still wider
range of vendor equipment.

97

REFERENCES

AIHW: Cancer in Australia: an overview, 2010. Cancer series no. 60. Cat.no. CAN
56. Canberra:AIHW
Airley R. 2009. Cancer chemotherapy: Basic science to the clinic. Wiley-Blackwell.
West Sussex, UK. Pp 55 – 67.
Alvarez-Moret J, Pohl F, Koelbl O, Dobler B. 2010. Evaluation of volumetric
modulated arc therapy (VMAT) with Oncentra MasterPlan® for the treatment
of head and neck cancer. Radiation Oncology 5: 110 – 120.
Amerio S, Boriano A, Bourhaleb F et al. 2004. Dosimetric characterisation of a large
area pixel-segmented ionisation chamber. Medical Physics 25(10): 1773 –
1829.
Antonuk LE. 2002. Electronic portal imaging devices: a review and historical
perspective of contemporary technologies and research. Physics in Medicine
and Biology 47(6): R31-R65.
ACR –ASTRO Practice Guideline for Intensity Modulated Radiation Therapy
(IMRT). 2011.
Attix FH. 1986. Introduction to radiological physics and radiation dosimetry.
Wiley-Interscience. Madison, Wisconsin. Pp 450-454.
Basran PS, Milton KW. 2008. An analysis of tolerance levels in IMRT quality
assurance procedures. Medical Physics 35(6):2300 – 2307.
Bedford JL, Warrington AP. 2009. Commissioning of Volumetric Modulated Arc
Therapy (VMAT). Int J Radiation Oncology Biol Phys 73(2): 537 – 545.
Budgell GJ, Zhang Q, Trouncer RJ et al. 2005. Improving IMRT quality control
efficiency using an amorphous silicon portal imager. Medical Physics 32(11):
3267 – 3278.
Butson MJ, Yu PKN, Cheung T and Alnawaf H 2010 Energy response of the new
EBT2 radiochromic film to x-ray radiation Rad. Meas. 45 836 – 9.
Cadman P, McNutt T and Bzdusek K. 2005. Validation of physics improvements for
IMRT with a commercial treatment planning system. JACAMP 6(2): 74 – 86.
Chang J, Ling CC. 2003. Using the frame averaging of aS500 EPID for IMRT
verification. JACAMP. 4(4): 287 – 299.
98

Chang SX, Cullip TJ, Deschesne KM et al. 2004. Compensators: An alternative
IMRT delivery technique. Journal of Applied Clinical Medical Physics. 5(3):
15-36.
Chen J, Lambert L, Weinberg V et al. 2011. Comparing Electronic Portal Imaging
and Megavoltage Conebeam CT for Positioning Head-and-Neck Radiotherapy
Patients. ASTRO Poster Presentation.
Chung H, Lynch B, Samant S. 2009. High-precision GAFCHROMIC EBT filmbased absolute clinical dosimetry using a standard flatbed scanner without the
use of a scanner non-uniformity correction. JACAMP 11(12): 101 – 115.
Chytyk K, McCurdy BM. 2009. Comprehensive fluence model for absolute portal
dose image prediction. Medical Physics 36: 1389 – 1398.
Chytyk-Praznik K, VanUytven E, van Beek TA, Greer PB and McCurdy BMC.
2013. Model-based prediction of portal dose images during patient treatment.
Medical Physics 40: 031713.
Clarke MF, Budgell GJ. 2008. Use of an amorphous silicon EPID for measuring
MLC calibration at varying gantry angle. Physics in Medicine and Biology 53:
473 – 485.
Constantinou C, Attix FH, Paliwal BR., 1982. A solid water phantom material for
radiotherapy x-ray and γ-ray beam calibrations. Medical Physics., 9: 436 – 441.
Das IJ, Ding GX, Ahnesjö A. 2008. Small fields: Non-equilibrium radiation
dosimetry. Medical Physics 35(1): 206 – 215.
Deshpande S, Vial P, Holloway L. 2011. 2-D radiation therapy dosimetry using
EPIDs: Dose response variation between 3 Siemens electronic portal imaging
devices (EPIDs). Radiation Measurements 46: 1916 – 1919.
Ding GX, and Munro P. 2011. Comparing MV and kV Imaging Doses for Image
Guided Radiation Therapy. ASTRO Abstracts # 3175, 2011.
ESTRO Booklet 9: GUIDELINES FOR THE VERIFICATION OF IMRT. ESTRO
Publications. Brussels, Belgium. 2008.
Ezzel GA, Galvin JM, Low D et al. 2003. Guidance document on delivery, treatment
planning, and clinical implementation of IMRT: Report of the IMRT
subcommittee of the AAPM radiation therapy committee. Medical Physics
30(8): 2089 – 2115.

99

Ezzel GA, Burmeister JW, Dogan N et al. 2009. Guidance document on delivery,
treatment planning, and clinical implementation of IMRT: Report of the IMRT
subcommittee of the AAPM radiation therapy committee. Medical Physics
36(11):5359 - 5373.
Greene D, Williams PC. 1997. LINACs for Radiation Therapy: Second edition.
Taylor and Francis Group, Madison, New York. Pp 169 – 173.
Greer PB, Popescu PP. 2003. Dosimetric properties of an amorphous silicon
electronic portal imaging device for verification of dynamic intensity
modulated radiation therapy. Medical Physics 30(7): 1618 – 1627.
Greer PB. 2005. Correction of pixel sensitivity variation and off-axis response of
amorphous silicon EPID dosimetry. Medical Physics 32(12): 3558 – 3568.
Greer PB. 2007. Off-axis dose response characteristics of an amorphous silicon
electronic portal imaging device. Medical Physics 34(10): 3815 – 3824.
Grein EE, Lee R, Luchka K. 2002. An investigation of a new amorphous silicon
electronic portal imaging device for transit dosimetry. Medical Physics
29(10):2262 – 2268.
Groh BA, Siewerdson JH, Drake DG et al. 2002. A performance comparison of flatpanel imager-based MV and kV cone-beam CT. Medical Physics 29(6): 967 –
975.
Gustaffson H, Vial P, Kuncic Z et al. 2009. EPID dosimetry: Effect of different
layers of materials on absorbed dose response. Medical Physics 36(12): 5665 –
5674.
Height FJ, Kron T, Willis D et al. 2012. Impact of MLC leaf width on the quality of
the dose distribution in partial breast radiotherapy. Medical Dosimetry 37(1):
37 -41.
Herman MG, Balter JM, Jaffray DA. 2001. Clinical use of Electronic Portal Imaging:
Report of AAPM Radiation Therapy Committee Task Group 58. Medical
Physics 28: 712 – 737.
Holmes TW, McCollough EC. 1983. Acceptance testing and quality assurance of
automated scanning film densitometers used in the dosimetry of electron and
photon therapy beams. Medical Physics 10: 698 – 704.
Huq MS, Das IJ, Steinberg T et al. 2002. A dosimetric comparison of various
Multileaf collimators. Physics in Medicine and Biology 47: N159 – N170.
100

IAEA TRS-398. 2004. Absorbed Dose Determination in External Beam
Radiotherapy: An International Code of Practice for Dosimetry based on
Standards of Absorbed Dose to Water. INTERNATIONAL ATOMIC
ENERGY AGENCY, Vienna, Austria.
ICRU Report 50: 1993. Prescribing, Recroding and Reporting Photon Beam Therapy
(ICRU Report 50), Journal of the ICRU.
ICRU Report 83: 2010. Prescribing, Recording, and Reporting Intensity-Modulated
Photon-Beam Therapy (IMRT)(ICRU Report 83), Journal of the ICRU Vol. 10
Jacobs M, Nijsten S, Minken A et al. 2005. Dosimetric calibration of a Siemens
OptiVue 500 amorphous silicon electronic portal imaging device. Department
of Radiation Oncology, University Hospital Maastricht, The Netherlands.
Jaffray D, Kupelian P, Djemil T et al. 2007. Review of image-guided radiation
therapy. Expert Rev Anticancer Ther 7(1): 89 – 103.
Javedan k, Stevens CW, Forster KM. 2008. Compensator-based intensity-modulated
radiation therapy for malignant pleural mesothelioma post extrapleural
pneumonectomy. JACAMP 9(4): 98-109.
Juste B, Miro R, Diez S et al. 2010. Monte Carlo simulation of the iViewGTTM portal
imager dosimetry. Applied Radiation and Isotopes. 68(4): 922 – 925.
Kahn FM. 2010.The Physics of Radiotherapy (4th Edition). Lippincott Williams and
Wilkins, Baltimore, USA. Pp 210-217.
Khan RFH, Ostapiak OZ, Szabo JJ. 2008. An empirical model of electronic portal
imager response implemented within a commercial treatment planning system
for verification of intensity-modulated radiation therapy fields. JACAMP 9(4):
135 – 150.
Kairn T, Cassidy D, Sandford PM et al. 2008. Radiotherapy treatment verification
using radiological thickness measured with an amorphous silicon electronic
portal imaging device: Monte Carlo simulation and experiment. Physics in
Medicine and Biology 53: 3903 – 3919.
Kairn T, Hardcastle N, Kenny J et al. 2011. EBT2 radiochromic film for quality
assurance of complex IMRT treatments of the prostate: micro-collimated
IMRT, RapidArc, and TomoTherapy.
Kirby MC and Glendinning AG. 2006. Developments in electronic portal imaging
systems. British Journal of Radiology 79: S50 – S65.
101

Kirkby B, Sloboda R. 2005. Consequences of the spectral response of an a-Si EPID
and implications for dosimetric calibration. Medical Physics 32(8): 2649 –
2658.
Klein EE, Hanley J, Bayouth J et al. 2009. AAPM Task Group 142 report: Quality
assurance of medical accelerators. Medical Physics 36(9): 4917 – 4212.
Kruse JJ, Herman MG, Hagness CR et al. 2002. Electronic and film portal images: a
comparison of Landmark visibility and review accuracy. IJROBP 54(2): 584 –
591.
Langmack KA. 2001. Review article: Portal imaging. British Journal of Radiology.
74(885): 789 – 804.
Lanz R, Zeugin F. 1998. Build-Up Algorithm for Dynamic Control of Multi-Leaf
Collimators

in

Radiation

Therapy.

Figure

obtained

from

website:

www.static.sws.bfh.ch/diplom/t38/t38_01/diplberi.html
Laub WU, Wong T. 2003. The volume effect of detectors in the dosimetry of small
fields used in IMRT. Medical Physics 30(3): 341 – 347.
Lee C, Menk F, Cadman P et. al. 2009. A simple approach to using an amorphous
silicon EPID to verify IMRT planar dose maps. Medical Physics 36(3): 984992.
Louwe RJ, Tielenburg R, van Ingen KM et al. 2004. The stability of liquid-filled
matrix ionisation chamber electronic portal imaging devices for dosimetry
purposes. Medical Physics 31(4): 819 – 827.
Louwe RJ, McDermott LN, Sonke JJ et al. 2004. The long-term stability of
amorphous silicon flat panel imaging devices for dosimetry purposes. Medical
Physics 31(11): 2989 – 2995.
Low DA, Harms WB, Mutic S et al. 1998.

A Technique for the Quantitative

Evaluation of Dose Distributions. Medical Physics 25(5): 656-661.
Low DA, Dempsey JF. 2003. Evaluation of the gamma dose distribution comparison
method. Medical Physics 30 (9): 2455-2464.
Mackie TR, McNutt TR, Paliwal BR,. 1997. Analysis and convergence of the
iterative convolution/superposition dose reconstruction techniques for multiple
treatment beams and Tomotherapy. Medical Physics. 24: 1465 – 1476.
Mail N, O’Brien P, Pang G. 2007. Lag correction model and ghosting analysis for an
indirect-conversion flat-panel imager. JACAMP 8(3): 137 – 146.
102

Mans A, Wendling M, McDermott LN et al. 2010. Catching errors with in vivo EPID
dosimetry. Medical Physics 37(6): 2638 – 2645.
McDermott LN, Louwe RJW, Sonke JJ et al. 2003. Dose–response and ghosting
effects of an amorphous silicon electronic portal imaging device. Medical
Physics 31(2): 285 – 295.
McDermott LN, Wendling M, van Asselen B. 2006. Clinical experience with EPID
dosimetry for prostate IMRT pre-treatment dose verification. Med Phys 33(10):
3921 – 3930.
McDermott LN, Wendling M, Sonke JJ et al. 2007. Replacing Pre-treatment
Verification With In Vivo EPID Dosimetry For Prostate IMRT. IJROBP 67(5):
1568 – 1577.
Meyer JL. 2007. IMRT IGRT SBRT Advances in the Treatment Planning and
Delivery of Radiotherapy. Karger, Basel, Switzerland. Pp 24-28.
Mijnheer b. 2008. State of the art of in vivo dosimetry. Radiation Protection
Dosimetry. 131(1): 117-122.
Moura FMG.2008. Amorphous silicon detector panel damage: correlating physical
parameters to clinical usability. Thesis, University of Lisboa, Lisbon, Portugal.
Mundt AJ, Roeske JC. 2011. Image-Guided Radiation Therapy: A Clinical
Perspective. People’s Medical Publishing House, Shelton, USA.
Nelms BE, Zhen H, Tomé WA. 2011. Per-beam, planar IMRT QA passing rates do
not predict clinically relevant patient dose errors. Medical Physics 38(2): 1037
– 1044.
Nijsten SMJJG, van Elmpt WJC, Jacobs M et al. 2007. A global calibration model
for a-Si EPIDs used for transit dosimetry. Medical Physics 34(10): 3872 –
3884.
Nijsten SMJJG, Mijnheer BJ, Dekker ALAJ et al. 2007(b). Routine individualised
patient dosimetry using electronic portal imaging devices. Radiotherapy and
Oncology 83: 65 – 75.
Niroomad-Rad A, Blackwell CR, Coursey BM et al. 1998. Radiochromic film
Dosimetry. Medical Physics 25(11): 2093 – 2115.
Olch AJ. 2002. Dosimetric performance of an enhanced dose range radiographic film
for intensity modulated radiation therapy quality assurance. Medical Physics
29(9): 2159 – 2168.
103

Otto K. 2007. Volumetric-Modulated Arc Therapy: IMRT in a single gantry arc.
Medical Physics 35(1): 310 – 17.
Palta JR, Kim S, Li JG et al. 2003. Tolerance Limits And Action Levels For Planning
And Delivery Of IMRT. Proceedings of the AAPM 2003 Summer School:
Intensity modulated radiation therapy: the state of the art. Colorado College,
Colorado Springs CO: Medical Physics Publishing (Madison, WI); 2003:593612.
Parent L, Fielding AL, Dance DR et al. 2007. Amorphous silicon EPID calibration
for dosimetric applications: comparison of a method based on Monte Carlo
prediction of response with existing techniques. Phys Med Biol 52: 3351 –
3368.
Partridge M, Ebert M, Hesse BM. 2002. IMRT verification by three-dimensional
dose reconstruction from portal beam measurements. Medical Physics 29(8):
1847 – 1858.
Pecharromán-Gallego R, Mans A, Sonke JJ. 2011. Simplifying EPID dosimetry for
IMRT treatment verification. Medical Physics 38(2) : 983 – 994.
Podgorsak EB. 2005. Radiation oncology physics: a handbook for teachers and
students. IAEA. Vienna, Austria. Pp 285-286.
Quinn A, Holloway L, Cutajar D et al. 2011. Megavoltage cone beam CT near
surface dose measurements: potential implications for breast radiotherapy.
Medical Physics 38(11) 6222 – 6227.
Radiological Imaging Technology Inc Homepage, http://www.radimage.com/,
Accessed November 2011.
RANZCR website: http://www.ranzcr.edu.au/advocacy/consumers/764-radiotherapytechnologies Accessed 17/01/2012.
Ravindran P. 2007. Dose optimisation during imaging in radiotherapy. Biomedical
Imaging and Intervention Journal 3(2):e23.
Schiffner DC, Gottschalk AR, Lometti M et al. 2007. Daily electronic portal imaging
of implanted gold seed fiducials in patients undergoing radiotherapy after
radical prostatectomy. IJROBP 67(2): 610 – 19.
Siebers JV, Kim JO, Ko L et al. 2004. Monte Carlo computation of dosimetric
amorphous silicon electronic portal images. Medical Physics 31(7): 2135 –
2146.
104

Spezi E, Angeli AL, Ferri A. 2006. A multiple acquisition sequence for IMRT
verification with a 2-D ion chamber array. Medical Dosimetry 31(4): 269 –
272.
Tyler M. 2008. Assessment of the sampling capabilities of the IBA I’mRT MatriXX
array in intensity modulated radiation therapy fields. Honours Thesis.
University of Wollongong, Australia.
Van Elmpt W, McDermott L, Nijsten S et al. 2008. A literature review of electronic
portal imaging for radiotherapy dosimetry. Radiotherapy and Oncology 88(3):
289 – 309.
Van Elmpt W, Ezzel GA, Orton CG. 2009. EPID dosimetry must soon become an
essential component of IMRT quality assurance. Medical Physics 36(10): 4325
– 4327.
Van Esch A, Depuydt T, Huyskens DP. 2004. The use of an aSi-based EPID for
routine absolute dosimetric pre-treatment verification of dynamic IMRT fields.
Radiotherapy and Oncology 71(2): 223 – 234.
Van Esch A, Clermont C, Devillers M. 2007. On-line quality assurance of rotational
radiotherapy treatment delivery by means of a 2D ion chamber array and the
Octavius phantom. Medical Physics 34(10): 3825 – 3837.
Van Zijtveld M, Dirkx MLP, deBoer HCJ et al. 2006. Dosimetric pre-treatment
verification of IMRT using an EPID; clinical experience. Radiotherapy and
Oncology 36(2): 168 – 175.
Vial P, Greer PB, Oliver L et al. 2008. Initial evaluation of a commercial EPID
modified to a novel direct-detection configuration for radiotherapy dosimetry.
Medical Physics 35(10): 4362 – 4375.
Wang CC. Clinical Radiation Oncology: Indications, techniques and results. 2nd
Edition. 2000. Wiley-Liss. New York. Pp 1-3.
Wang H, Dong L, O’Daniel J et al. 2005. Validation of an accelerated ‘demons’
algorithm for deformable image registration in radiation therapy. Physics in
Medicine and Biology 50(12): 2887.
Warkentin B, Steciw S, Rathee S et al. 2003. Dosimetric IMRT verification with a
flat-panel EPID. Medical Physics 30(12): 3143 – 3155.
Webb S. 2001 (a). Intensity-Modulated Radiation Therapy. Institute of Physics
Publishing. Bristol, UK.
105

Webb S. 2001 (b). The physics of three-dimensional radiation therapy: Conformal
Radiotherapy, Radiosurgery and Treatment Planning. Institute of Physics
Publishing. Bristol, UK.
Webb S. 2003. The physics basis of IMRT and inverse planning. British Journal of
Radiology. 76(910): 678 – 689.

Wendling M, Louwe RJW, McDermott LN et al. 2006. Accurate two-dimensional
IMRT verification using a back-projection EPID dosimetry method. Medical
Physics 33(2): 259 – 273.
Wigg DR. Applied Radiobiology and Bioeffect Planning. 2001. Medical Physics
Publishing. Madison, USA.
Winkler P, Hefner A, Georg D. 2005. Dose-response characteristics of an amorphous
silicon EPID. Medical Physics 32(10) 3095 – 3105.
Winkler P, Georg D. 2006. An intercomparison of 11 amorphous silicon EPIDs of
the same type: implications for portal dosimetry. Physics in Medicine and
Biology 51(17): 4189 – 4200.
Yu CX. 1995. Intensity-modulated arc therapy with dynamic multileaf collimator: an
alternative to Tomotherapy. Physics in Medicine and Biology 40(9): 1435 – 49.
Zhu XR, Jursinic DF, Grimm F et al. 2002. Evaluation of Kodak EDR2 film for dose
verification of intensity modulated radiation therapy delivered by a static
Multileaf collimator. Medical Physics 29(8): 1687 – 1692.

106

